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3To Hanne and Ulrik
Good judgment is the result of experience, and experience the result of bad 
judgment.
- Mark Twain
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1 Introduction
1.1 Coronary heart disease
Coronary heart disease is a major cause for morbidity and mortality throughout the 
world1;2. Owing to improved prevention, diagnosis and treatment, death rates have 
declined in North America and Western European countries3. Milestones include the 
identification of risk factors like smoking, high blood pressure and blood cholesterol, 
the emphasizing of early identification and treatment of heart attack, and treatment 
options like medication, percutaneous coronary intervention (PCI) and intensive care 
for the critically ill heart failure patient3.
Myocardial infarction is caused by interrupted blood supply to a part of the heart 
muscle, most commonly after occlusion of a coronary artery. After acute myocardial 
infarction (AMI) myocardial tissue goes through a process of necrosis, edema and 
inflammation, followed by fibroblast invasion and proliferation and the eventual scar 
formation with dense fibrous tissue without myocardial cell repair4;5. The scar is
characterized by thinning, elongation and reduced contraction, while the remaining 
undamaged part of the myocardium may change with hypertrophy and increased 
contraction. Especially in large, transmural infarcts of the left ventricle (LV) there is
risk of development of adverse remodeling, characterized by left ventricular 
enlargement, altered geometry and development of congestive heart failure4;6.
1.2 Stem cell treatment in myocardial infarct
At the turn of the millennium, reports on myocardial cell regeneration from bone 
marrow cells emerged7;8. Several clinical trials were initiated to explore the potential 
for myocardial cell repair from stem cells in a clinical setting9-13. In Oslo, the 
Autologous Stem Cell Transplantation in Acute Myocardial Infarct (ASTAMI) study 
was started in 2003, recruiting patients with AMI from Rikshospitalet University 
Hospital and Ullevål University Hospital14. The purpose was to assess whether stem 
cell therapy after AMI could facilitate relative preservation of LV function. 
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1.3 Imaging-based judgment of the infarcted left ventricle
1.3.1 Global left ventricular function
The vast majority of myocardial infarcts affect the free wall of the LV or septum and 
in the chronic phase the main interest is the LV function. A local damage directly 
influences the capability of the LV to compress and eject sufficient stroke volume. 
The global LV ejection fraction (LVEF) is the most commonly used measurement
for characterization of the LV function. Reduced LVEF is correlated to mortality and 
is still one of the most important prognostic determinants after myocardial infarct 15.
The calculation is based on measurements of end diastolic and end systolic volumes.
The result is given in percent from the equation
100u 
EDV
ESVEDVLVEF (1)
where EDV is end diastolic volume and ESV is end systolic volume. The LV may 
dilate with increasing EDV and ESV, compensating reduced LVEF with the 
preservation of stroke volume. The global LV function results from the sum of 
regional contraction. In spite of local damage, LVEF may be preserved. Thus, 
assessment of regional wall function adds more detailed information on LV function 
and even prognosis after myocardial infarct16.
1.3.2 Regional function
Correct anatomical assignment of myocardial segments is crucial for comparison of 
regional analysis between individuals and from one method to another. Currently, the 
17 segment model is most often used17. Some advantages of the model are the 
simplicity, the standardization of image planes combined with segmentation, 
standardization across modalities and a model for coronary perfusion territories. For 
long, qualitative assessment of regional wall motion has been performed with scoring
as normal, hypokinetic, akinetic or even dyskinetic with a diversity of methods18.
Regional wall motion score (WMS) further indexed represents an LV wall motion 
score index (WMSI)19.
Strain is defined as stress-induced relative deformation from the original or 
unstressed dimensions. The introduction of this deformation parameter increased the 
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ability to quantify regional movement of the LV20. The parameter is dimensionless, 
as deformation is viewed in relation to the initial length, but with a principal 
direction and may be expressed as a vector. Lagrangian strain is defined as 
deformation fraction:
0
0
L
LL  H (2)
where İ is Lagrangian strain, L = instantaneous length and L0 = initial length. Thus, 
shortening is negative İ, and thickening is positive. Strain rate is the time derivate of 
İ, measured in s-1 or 1/s. For one- or two-dimensional imaging systems İ has to be 
projected (Figure 1). In severe ischemia marked changes of local deformation 
patterns occur, with stretching during iso-volumetric contraction and shortening 
during early diastolic phase of dyskinetic regions21. Thus, studies on regional 
deformation with sufficient temporal differentiation enables even more detailed 
characterization of myocardial dysfunction.
Figure 1: Strain projections
Projection of myocardial İ
measurement into one of three 
directions, as viewed in relation to 
the LV wall. İL is deformation along 
the wall from base to apex (L). İC is
the deformation of the short axis 
circle (C), whereas İR defines the 
thickening or thinning of the 
ventricular wall parallel to the 
short axis diameter (R).
The myocardial structure of the LV is complex with the muscle wall organized in 
layers of different myofibrillar orientation. The inner, subendocardial layer and the 
outer, subepicardial layer form a couple of two opposite orientated helix bands, and 
between them there is a circumferentially orientated layer. The oblique fiber angle 
favors contraction and the ability to withstand wall stress. The anatomical 
architecture also explains the torsion of the ventricle with a counter-clockwise 
rotation of the apical part, as viewed from the apex, and the opposite rotation in the 
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basal part22. Tissue tracking methods have made it possible to follow the more 
complex, wringing movements of the LV, and calculate the magnitude of counter-
clockwise torsion of the apical part as seen from the apex, or the difference between 
the apical torsion and the opposite basal torsion (LV twist)23-25.
1.3.3 Tissue perfusion and microvascular obstruction
Tissue perfusion provides delivery of nutrition and O2 and clearance of CO2 and 
heat. Metabolism depends on sufficient microcirculation which is influenced by 
reduced coronary flow and might be altered in a variety of myocardial diseases 
including ischemia, infarct, inflammation and repair. Perfusion imaging is the 
registration of perfusion dependent tissue change over time, and is used for 
assessment of ischemia or microvascular disease. Classically, a diffusible tracer in 
the vascular bed is exchanged between the vascular compartment and tissue and 
influences characteristics of tissue imaging. A slice or a volume is repeatedly 
scanned for the visual registration of tissue differences due to tracer level 
inhomogeneity, or even a time curve with more quantitative regional scaling of the 
tracer is generated.
Stress perfusion imaging is by far the most common cardiac perfusion imaging 
acquisition. Stress is induced either with physical activity or pharmacologically; as 
vasodilator or ionotropic stress. The purpose is to achieve maximum coronary flow 
for the revelation of ischemia due to coronary stenosis, qualitatively assessed from 
reduced tracer quantities during first pass, reversible at rest. The method is 
considered a powerful non-invasive diagnostic tool in the work-out of suspected 
coronary ischemic disease26;27.
Commonly, acute or chronic infarct zones are shown to be hypoperfused during first 
pass of a tracer such as a contrast agent. The term microvascular obstruction (MO) 
designates a more prolonged or permanent hypoenhancement of the contrast medium
in the core of a reperfused myocardial infarct. MO has been closely linked to the no-
reflow or low-reflow phenomenon28;29. This phenomenon describes a zone of 
severely reduced flow in the infarct core in more extensively damaged tissue after 
prolonged ischemia and reperfusion. Capillary damage and small vessel obstruction 
have been suggested the major contributing factors of the phenomenon, possibly with 
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a role for blood viscosity30. Presence of MO is invariably related to larger infarct size 
and is considered an independent prognostic factor for adverse remodeling or 
cardiovascular events31-33.
The natural course is not described in detail. MO may be present immediately after 
the infarct. In dogs, MO increases over the first 48 hours after the incident29;34 and is 
present for several days35. In humans, the phenomenon has mainly been studied 
during the first week after AMI31;32;36-38; in a longitudinal study the number of 
patients with MO decreased from 2 days to 7 days after PCI, and the phenomenon 
was gone at 2 months33.
1.3.4 Infarct visualization
Direct in vivo visualization of myocardial infarct tissue is dependent on altered
cellular activity or tissue composition. Techniques of nuclear medicine are primarily 
based on cellular metabolism. The late gadolinium enhancement (LGE) technique of 
cardiac MRI is based on the increased extracellular volume in acute or chronic 
infarcts. LGE may not be specific per se, with the possible confusion with 
inflammatory tissue. Infarct size and transmurality are independently correlated to 
severity of the remodeling process4;38;39, thus precise anatomical characterization of 
the infarct supplies useful information for risk stratification and therapeutic 
monitoring. The superior spatial resolution of MRI is an advantage, making precise 
transmurality assessment possible. Grading of transmurality can be performed in two
principally different ways. Transmural extent is maximum transmurality of the 
infarct, as extent of the complete wall thickness, for example if the infarct affects less 
than or more than half of the complete wall thickness in a segment or perfusion 
territory. In computerized systems this grading has been averaged over a complete 
segment or area40;41. The other grading system is the percent scar42 of a segment or 
area. The two systems have been shown to score similarly with reference to İC43. In 
several studies transmurality has been classified as an ordinal parameter with 
transmural extent or percent scar in groups; most often categorized from 1 to 4 
representing increasing quartiles with no infarct classified as 0.
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1.4 Magnetic resonance imaging
Imaging modalities are techniques used for medical imaging. Examples are MRI, 
echocardiography, computed tomography, x-ray and fluoroscopy and a range of 
nuclear medicine techniques. MRI does not use ionizing radiation; it transforms 
differences in tissue magnetization into images by means of a very strong magnet, 
applied magnetic field gradients and transmitted radiofrequency (RF) pulses.
1.4.1 Motion
The movements of the heart make demands on short acquisition time, which in turn 
challenges additional MRI properties. An image of the beating heart has to be 
captured in small fractions of a second. To achieve time for enough phase encoding 
steps, the routine cardiac MRI sequence samples data at particular time points of the 
cardiac cycle for several cardiac cycles. The cardiac MRI sequence is synchronized
with the the patient’s ECG sampled simultaneously44. An anatomical image is the 
result of sampling from the similar equal delays after the “R” wave from several 
cardiac cycles. A series of images sampled at multiple time points, each image 
always at the same time point, in sum appear like a series of images from one cardiac 
cycle. This sampling at multiple time points of the heart cycle allows viewing of the 
series in a movie, known as a cine sequence. ECG triggering may be prospective
(RF-pulse initiated immediately after the “R”-wave) or retrospective which is useful 
when there are small beat-to-beat variations of the heart interval45.
Image acquisition in cardiac MRI is commonly performed during breath-hold to 
avoid motion artifacts from respiratory movements. Another option is to sample data 
at the same respiratory position by respiratory gating, most often performed with an 
edge-detecting algorithm at the lung/diaphragm border – called respiratory navigator 
technique46.
1.4.2 Foreign bodies and implants
Owing to the strengths of the static and oscillating magnetic fields of the MR system,
items brought into the magnet room like ferromagnetic foreign bodies or medical 
implants and devices, may represent hazard to the patient or other persons in the 
magnet room. Potential problems include objects acting like projectiles, items inside 
the patient getting displaced or torqued, medical devices making electric field 
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interactions, MRI-related heating, electromagnetic affection of the operation of an 
electric device or induction of currents in such, and implant-related artifacts. 
Undesired motion of the device is less likely with firm implantation.
Concern is about hazard to the patient, the understanding of artifacts, but also the 
inappropriate prevention from needed examinations. Testing methods have been 
established47-50, guidelines for industry have been published51, and comprehensive 
and detailed summaries on medical devices and contraindications are continuously 
updated52;53. Terminology changed in 2005. The term MR unsafe is for items posing 
hazard in any MR environment. MR safe is for nonconducting, nonmetallic, 
nonmagnetic items with no known hazard in any MR environment. MR conditional
is for items posing no hazard in specified magnetic environments. Technical 
development makes it necessary to continuously control unknown medical devices 
and implants in updated safety guideline databases and against the manufacturer’s 
handbooks and web pages. 
Some implants are especially relevant for cardiology54.
Sternal wires after sternotomy are MR safe. Most aortic stent grafts that have been 
tested are labeled MR safe, with an important exception regarding the Zenith AAA
Endovascular Graft® with components made from stainless steel. It is classified MR 
conditional, and has to be controlled against characteristics of the specific magnet.
Inferior vena cava filters are for most labeled MR safe, for some the waiting after 
implantation will allow firm implantation. Coronary and peripheral vascular stents
are labeled MR safe or MR conditional if they contain ferromagnetic components. 
Data for high-ILHOGPDJQHWV7LVQRWFRPSOHWHEmbolization coils made from 
nitinol, iridium and platinum are considered safe at field strengths 3.0 T and lower. 
Coils with ferromagnetic components are MR conditional, so allow time for firm 
implantation. In general, there is a theoretical potential for coil heating during 
examination. Cardiac closure devices from non-ferromagnetic materials are labeled 
MR safe. Again, some devices with ferromagnetic components are labeled MR 
conditional. Prosthetic heart valves and annuloplasty rings are either MR safe or for 
a lesser number MR conditional. In general, MR examination is not contraindicated, 
but there is a reservation for devices with minor ferromagnetic components in high-
field magnets. Traditional permanent cardiac pacemakers and implantable 
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cardioverter defibrillators (ICD) contain ferromagnetic components and complex 
electrical systems. Potential complications are displacement, damage and 
dysfunction of the device and cardiac stimulation and heating of the tip. However, 
several implanted pacemaker patients have undergone MR examinations; sometimes
unintentionally55-57. Very few serious complications have been reported57-61. At least 
three manufacturers now produce MR compatible pacemakers to be introduced in the 
MR environment under controlled circumstances62-68. Patients with retained 
transvenous pacemaker and defibrillator leads should not undergo MR examination. 
Temporary cardiac pacemakers contraindicate MR examination because of the 
external pulse generator. Retained temporary epicardial pacing leads do not pose a 
significant risk for MRI, at least as long as the leads are short and without large 
loops69. Hemodynamic monitoring and hemodynamic support devices like the Swan-
Ganz catheter, ventricular assist devices and intra-aortic balloon pumps are complex 
electric devices which contain ferromagnetic material and leads. These devices are 
MR unsafe.
1.4.3 Monitoring of the critically ill patient
Cardiovascular monitoring in the MR unit is demanding and the anesthetists miss
their usual access to direct patient contact. If critical illness occurs during an MR 
examination, either as worsening of the patient’s condition or as a complication to 
medication during the examination, resuscitation has to be initiated in the near 
vicinity of the MR suite. In a life support situation, staff members are called, and 
emergency equipment is in use. It is of high importance that these situations are 
handled outside the magnet room, in order to prevent ferromagnetic objects to act 
like projectiles, and to prevent entering of unauthorized staff members. These 
circumstances, added to the fact that hemodynamic support devices are MR unsafe, 
reduce the general access to MR examination for unstable and critically ill patients. 
1.4.4 Nephrogenic systemic fibrosis
Nephrogenic systemic fibrosis (NSF) was first diagnosed in 1997, with the first 
report published in 200070. The skin gradually thickens; there is fibrous proliferation 
and thickened collagen bundles, but no inflammatory signs. Extremities are affected, 
followed by the torso. Lungs, liver, esophagus, heart and muscle might become
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involved in patients with systemic affection. The patient may die from the disease. 
There is no known cure. The disease may stabilize spontaneously, but rarely remits71.
All patients diagnosed with NSF so far, have suffered from severe renal failure, and 
most were in need for treatment with hemodialysis70;71. In 2006 the first reports on a 
possible connection between NSF and gadolinium (Gd) based contrast agents were 
published72;73. Although the mechanism is not clarified, it is now believed that the 
administration of Gd based contrast agents in patients with renal failure carries a risk 
for NSF development, and the risk increases with lower residual renal function71;74;75.
Repeated administration and increased accumulated dosage of Gd increases the 
risk76. Metabolic acidosis and proinflammatory state, among other comorbidity, have 
been suggested to increase the risk. Incidence numbers from 3 % to 18 % have been 
reported among renal failure patients receiving Gd based contrast agents77, and 
hemodialysis has not proven to give preventive effect71. Symptoms develop up to 6 
months after Gd administration. Different classes of Gd chelate binding may carry 
different risk for the patient78.
In this light contrast agent administration for MRI is contraindicated in patients with 
severe renal failure79, but there is no known risk for patients with normal renal 
clearance (above 60 ml/min/1.73m2)80. International guidelines and 
recommendations have been developed to avoid the development of the disease80-82.
One main challenge is to identify patients with decreased renal clearance; another to 
avoid the inappropriate use of Gd based contrast agents.
1.5 Dynamic magnetic resonance imaging of the heart
In this respect, the meaning of the term “dynamic” is either of two:
x The image sequence displays the movements of the heart or the blood flow 
inside the heart and the great vessels.
x The image sequence detects myocardial signal intensity changes over time 
dependent on flow through the tissue; or detects signal intensity changes due 
to the injection of contrast agent, dependent on time from the injection.
Not all dynamic cardiac MRI is covered. MRI methods discussed in this thesis are 
cine imaging, tagging MRI, contrast-enhanced perfusion imaging at rest and LGE.
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1.5.1 Cine imaging
1.5.1.1 Bright blood sequences
Cardiac cine MRI is a technique where a set of images at the same slice position, are 
acquired at several time points throughout the cardiac cycle and shown sequentially 
to give the impression of the beating heart. Spoiled gradient echo (GRE) and 
balanced steady state free precession (bSSFP) pulse sequences are used for cine 
imaging. In spoiled GRE inflowing blood looks bright compared to the surrounding 
tissue, and in bSSFP blood signal is high due to the high T2/T1 of fluid. Thus, these 
sequences with good contrast to stationary tissue and vessel walls have been called 
bright blood imaging. The signal of blood in bSSFP is much higher than in spoiled 
GRE, increasing the contrast. On the other hand, signal of blood is more prone to 
flow artifacts in the spoiled GRE sequence, making the sequence more sensitive to 
jets from valvular disease.
Development of the bSSFP sequence led to several comparisons between the two 
methods83;84. In short, introduction of bSSFP provided increased signal to noise ratio, 
increased signal contrast and improved edge detection between blood and ventricular 
endocard. Higher signal enabled increased spatial and temporal resolution. 
Visualization of dephasing of the flow due to jets and regurgitations diminished. 
Measures of the LV changed slightly, with higher end diastolic and end systolic 
volumes, lower muscular mass, but without change of LVEF83. Inter-study 
reproducibility increased with bSSFP, and utilization of semi-automatic 
measurement software was made feasible84. As a result, the bSSFP has replaced the 
more traditional spoiled GRE sequence for cine cardiac MRI with magnetic field 
strengths below 3.0 T.
1.5.1.2 Left ventricular volume measurement
A method for numerical integration, the numerical approximation of definite 
integrals, is called “Simpson’s rule”; after the British mathematician Thomas 
Simpson (1719 – 1761). Even though the areas of the different slices in a stack 
usually are measured independently from each other, instead of performing 
approximation of integrals, summing up the areas is still called Simpson’s rule. The 
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method is independent from geometrical presumptions and has proven robust and 
reproducible in engineering, in medicine, as well as cardiology85;86.
A main advantage of cardiac MRI is the free choice of selecting any imaging plane, 
making imaging at reproducible cardiac axes possible. For heart volume 
measurement short axis slices aligned perpendicular to the LV long axis are utilized.
If breath-hold is not similar from slice to slice, significant through-plane movement 
occurs between the slices, reducing measurement precision. This latter problem is 
avoided with 3D acquisition of the complete ventricular complex with multiple slices 
in a single breath-hold, at the cost of reduced temporal and spatial resolution.
Calculation of LV EDV and ESV, and thus LVEF, rely on the precise identification 
of end diastolic and end systolic frames. The endocardial border has to be identified, 
but with manual delineation papillary muscles are included in the luminal area for 
practical reasons. The precise identification of the mitral valve plane (or for the right 
ventricle: the tricuspid valve plane) is a crucial point due to the relatively large short 
axis area at the basal cut edge of the ventricle. For myocardial muscle measurements 
also the epicardial contour has to be drawn. In order to save time numerous 
automatic and semi-automatic delineation software packages have been made87.
Alternatively, several models based on geometrical presumptions have been offered, 
in order to reduce number of delineated contours and calculation time. The 
“modified Simpson’s rule” is based on the LV long axis and two short axis areas, the 
“biplane ellipsoid formula” was based on the LV long axis and one long and one 
short axis ventricular area. Other models include the “hemisphere cylinder”, the 
“single-plane ellipsoid”88, and the “Teichholz formula”89. The biplane ellipsoid 
model has later been based on two perpendicular long axis areas and the LV long 
axis90-93. All models have been tested to some extent with variable results88. As a 
general objection, the different geometric presumptions are believed to be more 
accurate in normal LVs or in LVs with global pathology than in an LV remodeled 
from regional myocardial pathology. 
1.5.2 Cardiovascular magnetic resonance tagging
Tagging is the magnetic marking of tissue or fluid immediately followed by an MR 
sequence with the intention to track movement or deformation over time. By 
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introduction in 1988, this was the first noninvasive method to visualize transmural 
myocardial movement94;95. Most tagging techniques are still based on linear or grid 
demagnetization of tissue, appearing as hypodense stripes. With movement of the 
tissue, the lines move and deform, and the pattern and amplitude of displacement 
reflect tissue motion. The direct, qualitative judgment of the tagging sequence is 
possible, but the ability to quantify regional movement and deformation non-
invasively was an important progress.
Pulse sequences and initial tissue tagging have become faster, more flexible and with 
higher contrast96. The problem of early fading of tags due to tissue remagnetization 
has been reduced97. 3D tagging sequences have been introduced98. Not least, semi-
automatic analysis tools have been developed, thereby reducing post-processing time 
dramatically99;100.
In 1989, the spatial modulation of magnetization (SPAMM) technique was 
introduced with a combination of two non-selective RF-pulses separated by a weak 
dephasing gradient pulse. The stripes had a regular pattern with a sinusoidal intensity 
profile101. The SPAMM technique was almost immediately modified with more RF-
pulses of varying amplitudes, again separated by dephasing gradient pulses, thereby 
increasing tag contrast102. To overcome the problem of tag fading, the 
complementary spatial modulation of magnetization (CSPAMM) technique was 
constructed. The technique increased tagging amplitude and tissue signal at later 
phases; thereby increasing tag contrast and providing visualization of deformation in 
late diastole as well. The disadvantage was the doubling of the acquisition time97.
Different approaches for tagging analysis have been introduced. Methods like active 
contour, optical flow, template matching, sinusoidal analysis and grid line detection 
with snakes were all characterized by long processing time95. In 1995 an automated 
Fourier based algorithm for the tracking of SPAMM tags was proposed and initially 
validated103.
The harmonic phase (HARP) technique also utilized the Fourier domain in which the 
SPAMM tag pattern produces an underlying array of spectral peaks. The information 
from each of these peaks yields a complex harmonic image, and a harmonic 
magnitude and harmonic phase image can be reconstructed. The harmonic phase 
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image contains information on myocardial motion, and this motion is tracked by the 
analysis of the HARP angle. This tracking is principally independent from the tags, 
and the method reduced noise and increased resolution. When the analysis program 
was introduced, the HARP technique was semi-automated requiring the tracking of a 
subendocardial and subepicardial circle on short axis reconstructed images for the 
subsequent immediate estimation of radial or circumferential Lagrangian strain (İR
and İC). Manual correction of erroneous tracking (tag jumping) was required. 
However, the post-processing time was dramatically reduced compared to earlier 
methods99. The method was further validated in experimental and patient studies104-
106. The Multi-Ethnic Study of Atherosclerosis has demonstrated the potential for İ
examinations of larger populations with the HARP tool107-110.
1.5.3 Perfusion magnetic resonance imaging
In paper II, perfusion imaging was performed with Dynamic contrast-enhanced 
imaging (DCE MRI), which is the method to be discussed. In DCE MRI, T1-
weighted images are acquired repeatedly during the infusion of a T1-enhancing 
contrast agent. The signal intensities of the arterial bed and subsequently the tissue 
are enhanced, and the dynamic signal intensity registration over time enables 
characterization of tissue perfusion. The consequent mathematic relationship 
between perfusion and signal change is, among other factors, dependent on 
negligible susceptibility effects from the contrast agent injected.
1.5.3.1 Technique
A fast GRE sequence after a non-selective saturation pulse has made it possible to 
image a stack of 3 to 5 images during each RR-interval with stable T1 contrast over a 
broad spectrum of contrast concentration. Later, bSSFP with shorter acquisition time 
and higher signal to noise ratio, and different hybrid techniques with echo-planar
imaging and non-cartesian k-space trajectories have been introduced.
Contrast medium injection has to be sufficiently fast. If not, sensitivity for changes in 
myocardial blood flow is limited. An injection rate in the range of at least 3 ml/s is 
recommended. Injection dosage determines signal increase in the LV cavity and 
myocardial tissue111. A sufficiently high dose is convenient for the qualitative 
judgment of myocardial perfusion. The quantitative analysis of myocardial tissue 
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perfusion is dependent on correlation to an arterial input function (AIF) most often 
from the LV cavity or aortic lumen. For high concentrations, there is a non-linear 
relationship between contrast agent concentration and signal intensity, due to T2* 
effects.
The qualitative work-out of myocardial perfusion imaging is simply the visual
judgment of tissue enhancement during contrast medium first pass. Regions of 
hypoenhancement are noticed. Quantitative analysis is the mathematical analysis of 
measurements of tissue enhancement during first pass or longer. The latter is based 
on intensity values from the time intensity curves (TICs) measured in regions of 
interest (ROI) of myocardial tissue and LV lumen.
The analysis of the endocardial border remains a challenge in perfusion imaging, 
irrespective whether analysis is qualitative or quantitative. Partial volume effects and 
spill over from high intensity contrast filling of the LV cavity make border tracking 
challenging, and may reduce thickness of measurable myocardium especially in the 
apical regions. More often, a so-called dark rim artifact affects reading. This artifact 
is transient and peaks with maximum LV contrast filling and may precede contrast 
arrival of myocardial tissue112. The artifact is reduced with increasing spatial 
resolution, which increases demands on image quality and may affect temporal 
resolution112;113.
1.5.3.2 Quantitative assessment of dynamic contrast-enhanced MRI
Numerous perfusion parameters have been reported, with differing nomenclature. In 
paper II we mainly kept to one set of standardized quantities and symbols114.
Perfusion is tissue blood flow (TBF) per mass of tissue per time, often expressed in 
ml/100 g/min. Tissue blood volume is the fraction of tissue volume occupied by 
vessels. Mean transit time is mean time for a particle to be occupied in the volume 
considered. Mean transit time depends on tissue blood volume, blood velocity and 
vascular architecture. 
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The central volume principle defines the relationship:
TBF
TBVMTT   W (3)
where Ĳ and MTT denote mean transit time, TBV is tissue blood volume and TBF is 
tissue blood flow. Neither of these parameters is directly measurable, and we 
approach the calculation indirectly.
The T1 positive contrast agent rapidly injected is a water soluble tracer introduced 
into a fluid flowing at unknown rate through a system of unknown distribution 
volume. In this respect the tracer is extracellular and crosses the vascular wall rapidly 
and distributes into the extravascular, extracellular space (EES). With DCE MRI the 
effect of the tracer upon tissue signal is measured at a sampling site over appropriate 
time intervals, some place downstream from the injection site. 
Some tissue parameters of interest are directly derived from the TIC, but have to be 
considered together with information from AIF. The AIF is easily accessible in 
myocardial perfusion imaging from the aortic or LV lumen. Peak intensity is the 
maximum intensity value of either AIF or tissue measured. Time to peak (TTP) is the 
time to the peak intensity value of the curve. Here, TTPn and TTPi denote normal 
and infarct tissue TTP, respectively. Increased tissue TTP could be an indication of 
arterial collateral circulation or stenosis, but has to be correlated to the contrast 
arrival time. Initial upslope of the curve is the direct derivation of the initial intensity 
rise and is related to tissue flow and contrast agent leakage. Area under the curve 
(AUC) is the integral of the intensity-time curve of AIF or tissue. AUC up to AIF 
first pass peak is closely related to tissue volume. Parameters directly derived from 
the TIC are called descriptive enhancement parameters in this work. They are 
influenced from individual hemodynamics and infusion variations. This latter 
influence acts directly through the arterial input. Hence normalization to the AIF 
provides the possibility for a more general understanding of descriptive enhancement 
parameters. 
Intravascular space is the volume of the blood vessels, approximately 2-10% of 
different tissue volumes. The plasma volume fraction of the intravascular space is the 
intravascular distribution volume for intra- and extravascular contrast agents. EES is 
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the extravascular extracellular space; that is the interstitium excluding the 
intracellular space. ve is the EES volume fraction (of the whole volume); the 
extravascular distribution volume for contrast agents. The MR signal is registered 
from a tissue voxel of known volume with unknown ve and unknown vascular 
volume with unknown plasma volume fraction.
The two-compartment model
Shortly after the contrast agent has reached the vascular bed of a tissue volume, it
distributes into the extravascular space. Some contrast agent returns to the vascular 
bed. The distribution takes some time, dependent on flow, the area and permeability 
of the vascular bed, and the extravascular distribution volume. Ktrans is the transfer
constant from the vascular compartment to the EES. kep is the rate constant for the 
reflux from the EES back to the vascular component. The relationship between these 
parameters is illustrated in the two-compartment model (Figure 2) and is given by 
equation (4):
e
trans
ep v
Kk  (4)
A so-called mixed model describes the situation when Ktrans is dependent on TBF, 
and influenced by endothelial permeability and recruitment of myocardial capillaries. 
P is the permeability and S is the surface area of the capillary bed, together they form 
the PS product. TBF and the PS product do not vary independently, as vasodilatation 
probably is followed by capillary recruitment and increase of the capillary bed 
area115. With limited flow and high PS product (PS >> TBF), Ktrans is directly 
proportional to flow. With limited permeability and sufficient flow (TBF >> PS), 
Ktrans is determined by the PS product of the capillary wall and the concentration 
gradient114.
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Figure 2: The two-compartment model
A simplified illustration of 
the two-compartment 
model for contrast agent 
transfer between tissue 
compartments
The box illustrates an 
arbitrary voxel of tissue 
and the cylinder is the sum 
of vessels within. An 
extracellular contrast 
agent is distributed in 
plasma and interstitial 
water and exchange 
between these
compartments.
Deconvolution and the residue curve
The tissue concentration curve of a tracer is dependent on an idealized tissue 
response of a tracer bolus transferring the tissue, and the arterial input of the tracer. 
The relationship is described in equation (5) as the convolution of the input and the 
response curve116:
   tRAIFttissue  (5)
where tissue(t) is tissue tracer concentration at time t,  denotes convolution and R 
is the response curve. Assuming a linear relationship between tracer concentration 
and tissue signal the residue function, resembling the response curve, can be derived 
from a deconvolution process of tissue TIC to AIF. Fitted signal TICs include 
estimates of the kinetic parameters Ktrans and kep and the volume parameters ve and
plasma volume fraction (vp). The instant, maximum value of the residue curve is an 
approximation to tissue flow (rBF)117-119. An example of tissue TICs deconvolved to 
AIF with the resultant residue curves is shown in Figure 3.
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Figure 3: Time intensity curve and residue curve
Top: TICs from AIF (red), normal tissue (green) and infarct tissue (yellow), 
respectively. Blue and purple dotted curves represent fitted curves after 
deconvolution to AIF.Bottom: Two residue curves of normal (blue) and infarct 
tissue (purple) from AIF deconvolution
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The deconvolution process is mathematically unstable, and different approaches have 
been introduced to calculate the residue curve in a stable manner113. Additional 
mathematical modeling is needed to eliminate the fact that tissue tracer also has 
contributions from tracer recirculation. Any realistic modification of the two-
compartment model including added tissue compartments makes modeling more 
complex. The model’s dependency on a proportional relationship between contrast
concentration and signal intensity is crucial. True quantification is dependent on
some correction method in order to avoid T2* effects of the AIF, for instance 
sufficiently low contrast agent dosage.
1.5.3.3 Assessment of microvascular obstruction
Originally, MO detection with MRI was described as stable hypoenhancement in the 
infarct zone after first pass perfusion, 1 – 2 min after contrast agent injection28;120.
Diagnosis depends on T1 imaging at a time point in advance of LGE imaging. 
However, non-enhancing areas of the infarct core detected at LGE are similarly 
considered areas of infarct without reperfusion, and have been called severe, late or 
persistent MO32;38;121. Thus, separation into MO and persistent MO is possible, 
provided that early enhancement and LGE imaging is performed31;33. A potential
source of error was revealed in an experimental model with part of an acute infarct 
completely unperfused. This part may still be hyperintense on LGE imaging, if signal 
intensity of the sequence chosen is dependent on the amplitude of the magnetization 
vector122.
1.5.4 Late gadolinium enhancement
Until the late 1990s infarct characterization with MRI was dependent on the precise 
characterization of regional function. In 1999 Kim et al. utilized the fact that acute 
and chronic infarcts retain extravascular, extracellular contrast media to a larger 
extent than viable myocardium does, irrespective of whether the cells are ischemic or 
not. Infarct delineation between MRI and stained tissue slices correlated 
remarkably123. The main advantage of the new strategy was the ability to differentiate 
infarcted myocardium from hypokinetic tissue due to reversible ischemia. The 
breakthrough was facilitated by the introduction of two practical working methods. 
Infarct imaging was started at least 5 min after contrast agent injection and an 
inversion recovery sequence provided maximum T1 contrast. The method has gained 
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widespread use and different terms have been introduced, such as “late 
enhancement” (LE), “delayed enhancement” (DE), “delayed hyper-enhancement” 
(DHE) and late gadolinium enhancement (LGE); the latter term is used in this thesis.
Immediately after myocardial infarct, cell membranes of the necrotic cardiomyocytes 
disintegrate. Later necrotic tissue is replaced by granulation tissue and subsequently 
by scar tissue with collagen deposits in the extracellular matrix124. In all these stages 
of infarction disease the distribution volume of extravascular, extracellular molecules 
is increased, causing increased tissue concentration of extracellular contrast agents, 
and thus shortened T1. Five minutes after a bolus injection of contrast agent steady 
state has occurred with a stable contrast agent ratio between tissue and plasma115, and 
imaging is preferably initiated 10 minutes after contrast agent injection. Maximum 
T1 contrast is facilitated by the initial inversion recovery pulse, with an inversion 
time chosen to null viable myocardium which therefore appears dark, whereas non-
viable cardiac tissue appears bright. Sequential adjustment of inversion time is 
recommended due to renal clearance of contrast agent and gradually increasing 
T1120;125.
The detection of any focal area with increased extracellular volume is in itself 
unspecific. A diversity of cardiac pathologies includes the positive finding of LGE, 
but pattern of LGE and clinical picture vary126. The subendocardial to transmural 
LGE distributed in distinct coronary perfusion areas is highly specific for ischemic 
heart disease, and according to the Consensus Panel Report of 2004 LGE was 
considered a first line imaging method in the assessment of myocardial viability and 
the characterization of acute and chronic myocardial infarction127.
The extent of infarct affection is of great interest after an acute infarct, and in the 
preoperative assessment before coronary revascularization. Infarcts may more or less 
affect the complete myocardial wall, and this depth of infarct from the endocardial 
border is called transmural affection. Transmurality is closely related to infarct size 
and prognosis, and has been found to correlate independently with remodeling and 
function38. The presence of a thin subepicardial non-enhancing wall is not sufficient 
to obtain increased function after revascularization. One study defined a threshold of 
75 % transmurality a possible cut-off value for recovery after coronary artery 
reperfusion in chronic ischemic disease 42. On the other hand, other studies have 
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found a threshold of 50 % more convenient; as releated to likelihood for recovery in 
AMI or after bypass surgery127.
1.5.5 Cardiac magnetic resonance imaging challenges
Some inherent methodological sources of error apply for almost all cardiac MRI. 
They occur even under optimal conditions, and some are common for all dynamic 
cardiac imaging. Probably it is fair to emphasize that in spite of the sources of error 
below, MRI has a well documented potential for systematic, reproducible and non-
subjective reporting of the heart and the heart’s movements. 
Depending on level of inhalation during a breath-hold, heart position will vary more 
or less in all three standard axes from one acquisition to another. An apico-basal or 
LV axis translation between acquisitions may result, causing the undetected 
repetition or omission of one or more slices during the serial short axis imaging of 
the ventricular complex.
For short axis cine and tagging sequences the tissue at diastole is not completely 
similar to the tissue at systole, due to the heart’s LV axis translation during 
contraction and relaxation. The error is larger for the basal slices. 
With some pulse sequences, there may be a delay of 30-50 ms from the R-wave to 
acquisition of the first image. Furthermore, with prospective ECG trigging, the last 
image is acquired with a time margin until next R-wave to compensate for variations 
in the R-R interval. Thus cine and tagging sequences may miss part of the end 
diastolic phase.
Abrupt contour changes or signal variation of less than the complete slice thickness
may be masked or blurred123. This partial-volume effect is present in all cross-
sectional slice imaging, but increases with slice thickness and may be amplified by 
LV axis translation. 
With the exception of ultra-fast acquisition techniques which may allow real-time 
imaging, one cardiac pulse sequence typically encompasses 6 to 10 heart cycles. The 
combination of cycles makes cardiac MRI prone to motion artifacts, especially in 
arrhythmia.
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1.6 Two-dimensional speckle tracking echocardiography
Echocardiography is ultrasound examination of the heart. Pulses of ultrasound are 
transmitted into the tissues, and images are based on the reflected echoes. Reflections 
occur whenever there is a change in acoustic impedance, which is the product of 
tissue density and ultrasound propagation speed. Speckles are complex grayscale 
variations, mainly resulting from multiple reflections and the interference from these 
due to microscopic change in tissue structure. For most diagnostic ultrasound they
are considered noise distorting fine details of anatomy128. The speckles form an
acoustic pattern which is visible in the grayscale image or can be read directly from 
the received RF signal. For myocardial tissue, this pattern is considered unique for 
small units of tissue volume, like a finger print. Thus, a small tissue volume or area 
can be re-identified from image frame to image frame. Computerized identification 
and tracking of the specific speckles form the base for the characterization of tissue 
motion with this method.
Common 2D grayscale echocardiography of the heart in standardized image planes 
are utilized for the application of two-dimensional speckle tracking 
echocardiography (2D-STE). Quality of tracking is dependent on several factors, like 
the sufficient delineation of the myocardial wall and endo- and epicardial borders, 
the avoidance of reverberation artifacts and an adequate frame rate for the tracking of 
either grayscale or RF speckles. Speckles may change, disappear due to translation 
from the image plane, or deform. Generally, motion tracking is noisy, and some 
regularization filtering is applied, in order to secure a logical interpretation.
Tracking of speckles gives information of velocity, direction and deformation as a 
result of velocity differences between speckles. Thus, motion can be decomposed 
upon one of the preferred directions and characterized by in-plane strain rate or İ.
The technique is independent from insonation angle and with sufficient computer 
capacity it is quick. 
On this background, when 2D-STE was introduced, hope was that the method was 
able to characterize regional deformation of the LV, as expressed in İ or strain rate, 
perhaps with even better performance than traditional echocardiographic methods. 
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2 Aims
In the broader perspective the aim of this thesis was to illustrate the potential for 
MRI as a research tool in myocardial infarction.
2.1 Specific aims
The aim of paper I was to explore whether intracoronary injection of autologous 
mononuclear bone marrow cells (mBMC) after AMI influenced regional myocardial 
function or twist. Further, we aimed to explore the potentials for tagging analysis to 
detect more subtle changes in myocardial function than those detected by more 
routinely used examination techniques.
In paper II, the aims were to follow the semi-quantitative parameters from 
comprehensive analyses of contrast-enhanced myocardial perfusion imaging of 
infarct tissue, longitudinally from subacute to chronic phase. Furthermore we aimed 
to correlate the semi-quantitative measurements of subacute infarct tissue to more 
qualitative enhancement analyses from both perfusion imaging and LGE.
In paper III, we hypothesized that peak systolic longitudinal strain (İL) measured by 
2D-STE provided additional information regarding the extent of infarct mass and 
myocardial function when compared with the LVEF and WMSI in patients with 
chronic myocardial infarct. LGE was used as a reference method for determination 
of the infarct extent.
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3 Material and Methods
3.1 Patients and controls
Paper I and paper II were based on the ASTAMI study which was a prospective,
open-labeled, randomized trial. The study was designed with a power of 80 % to 
identify a potential difference of 5 % points in the development of LVEF between 
the treatment group and the control group, as measured by single-photon-emission 
computed tomography. A cohort of patients with ST-segment elevation acute 
myocardial infarction (STEMI) admitted for acute PCI at Rikshospitalet University 
Hospital and Ullevål University Hospital were screened for inclusion in the study 1 –
4 days after PCI. After acceptance, 101 patients were randomized by a permuted 
block randomization stratified according to study center to either treatment with 
intracoronary injection of mBMC or control. Block size was 4, randomization was 
1:1. For the treatment group, mBMC injection was performed 4 – 8 days (mean 6
days) after PCI. The combined procedure of bone marrow aspiration and 
intracoronary injection of placebo medium was considered unethical, thus controls 
received no intracoronary sham injection. One patient was later excluded due to heart 
transplantation. At 6 months all were alive, and no patient was lost in the follow-up.
Also see the publication for the trial’s main end points for details of inclusion14.
The MRI examination was performed 2 – 3 weeks after the acute infarction in order 
to avoid the effect of acute edema, and repeated at 6 months after the insult. At 6 
months there were 87 complete pairs of MRI examinations. All MRI examinations 
included cine imaging, contrast enhanced perfusion at rest and LGE. Midway in the 
ASTAMI study, the MR unit went through a hardware and software upgrade. bSSFP
method for cine imaging was introduced, and the perfusion sequence had been 
changed with altered dynamic range.
At the end of the trial myocardial tagging was included in the protocol. In paper I 28 
patients were included with a protocol of tagging MRI, cine imaging and LGE.
In paper II, 63 patients with paired perfusion MRI either before (n = 39) or after 
upgrade (n = 24) were included. Before upgrade the perfusion sequence was unstable 
and aborted early after AIF second pass peak during the run of 6 patients at baseline 
and 3 at 6 months. In these, only first-pass descriptive enhancement parameters were 
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measured. Three additional perfusion examinations were lost for qualitative first pass 
enhancement and MO assessment at baseline due to image noise. One patient refused 
the final contrast agent injection at 6 months and was excluded for LGE analysis. 
Thus 54 patients were included for all analyses. Most patients from paper I were also 
included in paper II.
Paper III was designed as a cross-sectional study of 38 patients included after an 
index STEMI, treated by PCI. None of the patients were in cardiogenic shock. MRI 
and echocardiography was performed at follow up, 9.2 ± 5.7 months after PCI. In 
addition, 15 healthy volunteers of the age 46 ± 12 years (6 female) were included for
echocardiography examination. See Table 1 for the comparison of patient 
characteristics in paper I – III.
All studies comply with the Declaration of Helsinki. The protocols were approved by 
the regional committee for research ethics. All subjects gave written, informed 
consent.
Table 1: Characteristics of patients included in paper I - III
Paper I Paper II Paper III
Patient number (female) 28 (6) 63 (9) 38 (10)
Intracoronary mBMC 15 30 -
Age (years) 59 ± 9 57 ± 9 55 ± 10
LVEF (%) 52 ± 10 55 ± 12 58 ± 11
LV EDV (ml) 176 ± 50 166 ± 43 157 ± 53
Infarct size (%) 24 ± 13 22 ± 14 20 ± 13
Anterior wall infarct 28 63 33
Inferior wall infarct 1 - 6
Lateral wall infarct 2 - 3
3HDN&.0%ȝJO 361 ± 136 322 ± 137 301 ± 188
In paper I and II characteristics of study patients at baseline; in paper III LV
volumes, infarct size and infarct location from follow-up MRI.G
3.2 Imaging methods
All MRI pulse sequences were acquired in the same image session with 1.5 tesla 
units (Magnetom Vision Plus or Magnetom Sonata, Siemens Healthcare, Erlangen, 
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Germany) using a phased array body coil. The different imaging modalities, analyses 
and outcome parameters are referred in Table 2.
Echocardiographic examinations were performed with either a Vivid 5 scanner 
(seven examinations) or a Vivid 7 scanner (46 examinations) (GE Healthcare 
Vingmed Ultrasound AS, Horten, Norway), using a phased-array transducer.
Table 2: Imaging and outcome parameters of papers I – III
Modality Analysis Outcome parameter
Paper 
I
Paper 
II
Paper 
III
Cine MRI Biplane LVEF X X
Echocardiography
Area biplane LVEF X
Visual assessment WMS, WMSI X
Tagging MRI HARP software İc, twist X
2D-STE EchoPac software İL, PSSI,            
early stretch
X
Perfusion MRI
TICs enhancement parameters X
Deconvolution Ktrans, kep, ve X
Residue curve rBF X
Perfusion MRI  
and LGE Visual assessment
enhancement 
groups X
LGE Manual contours infarct size X X X
The different modalities, analysis methods and outcome parameters of paper I - III.
LVEF: Left ventricular ejection fraction, WMS and WMSI: wall motion score
(index), HARP: Harmonic Phase Imaging, İC: circumferential strain, İL:
longitudinal strain, PSSI: post-systolic shortening index, 2D-STE: two-dimensional 
speckle tracking echocardiography, TIC: time intensity curve, Ktrans: the transfer 
constant, kep: the rate constant, ve: volume fraction of extravascular, extracellular 
tissue, rBF: parameter resembling blood flow from the residue curve, LGE: late 
gadolinium enhancement.
MRI cine imaging was performed to quantify LV volumes in papers I and III. 
Tagging MRI was performed in paper I for the assessment of regional İC and global 
LV twist. Perfusion MRI was performed in paper II with the measurement of a 
spectrum of descriptive enhancement and kinetic parameters, and visual assessment 
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of perfusion images together with LGE was performed for enhancement grouping. 
Echocardiography was performed for paper III. From grayscale echocardiography 
LV volumes and regional WMS and global WMSI were assessed. Additionally 2D 
grayscale images were analyzed with speckle tracking for İL, early stretch and post-
systolic shortening index (PSSI). For all papers regional and global infarct size was 
assessed with LGE. See papers I – III for more detailed method description.
3.3 Blinding of readers and variability assessment
All MRI analysis of the ASTAMI study was performed by readers blinded to 
treatment allocation.
For paper III, analyses of grayscale echocardiography, speckle tracking and MRI 
were performed independently by three different observers, blinded to the other 
results.
Inter- and intraobserver variability assessment of LVEF from cine MRI was 
performed for the ASTAMI study.
In paper I, İC and twist inter- and intra-observer reproducibility was assessed 
through repeated analyses of 10 randomly selected tagging examinations. 
Reproducibility of analyses was assessed with two-way mixed absolute agreement 
intraclass correlation analyses of global and regional İC and twist.
In paper II, the MO classification was performed by two independent observers, and 
decided by consent when disagreement occurred.
In paper III, echocardiography examinations were performed repeatedly by two 
independent observers on ten randomly selected patients. Repeated 
echocardiography was assessed with reliability analyses of İL values.
3.4 Statistical analyses
Continuous data are presented as mean ± standard deviation (SD).
In paper I, development of treatment groups between 2-3 weeks and 6 months was 
assessed by analysis of covariance, with the baseline values used as a covariate.
In paper II, paired samples t-tests were performed for the comparison of parameters 
of normal myocardium versus infarct tissue at baseline and for infarct intra-group 
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changes. Kruskal-Wallis test was performed to assess differences across the four 
enhancement groups. If difference was significant, follow up Mann-Whitney U test 
was performed for difference between pairs of groups with Bonferroni adjustment of 
the alpha level to 0.008. 
In paper III differences between myocardial tissue infarct categories were analyzed 
with one-way analysis of variance. Bonferroni correction was applied for post-hoc 
tests and for multiple regression analyses. Values were compared for correlation by 
regression analysis using a least squares method. A multivariate regression analysis 
was performed to find the best determinant of the global İL. Receiver operating 
characteristic (ROC) curves were constructed, and AUCs were measured to 
determine cut-off values for optimal sensitivity and specificity. The ROC analyses 
were VHWWRLGHQWLI\LQIDUFWVRI 30 g at the global level, an infarct size that has been 
shown to predict poor prognosis28, LQIDUFWVL]H 5 g at the territorial level and 
transmural infarct at the segmental level.
Tests were two-sided, and p-values < 0.05 were considered significant. SPSS 
software versions 16.0, 18.0 and 14.0, respectively (IBM Corporation, New York, 
NY, USA) were used.
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4 Summary of results
4.1 Paper I
In the control group myocardial function as measured by İC improved for the global 
LV (6 months: -13.1 ± 2.4 % versus 2 – 3 weeks: -11.9 ± 3.4 %, p = 0.014) and for 
the infarct zone (-11.8 ± 3.0 % versus -9.3 ± 4.1 %, p = 0.001), and significantly 
more than in the mBMC group (inter-group p = 0.027 for global İC, respectively p =
0.009 for infarct zone İC). LV infarct mass decreased (35.7 ± 20.4 g versus 45.7 ± 
29.5 g, p = 0.024), also significantly more pronounced than in the mBMC group 
(inter-group p = 0.034). LV twist was initially low and remained unchanged 
irrespective of therapy.
Mean intraclass correlation coefficient (ICC) of agreement for inter-observer 
judgments was 0.97 (with 95 % confidence interval 0.87 - 0.99), 0.96 (0.83 - 0.99) 
and 0.95 (0.65 - 0.99) for global, infarct zone and transmural infarct zone İC,
respectively, and corresponding values for intra-observer observations were 0.99 
(0.95 - 1.00), 0.98 (0.81 - 0.99) and 0.96 (0.82 - 0.99). For individual segments 
agreement was lower with an ICC of 0.81 (0.75 - 0.86) for intra-observer and 0.87 
(0.83 - 0.91) for inter-observer judgments. For twist analysis the ICC of agreement 
for inter-observer judgments was 0.92 (0.74 - 0.98) and 0.96 (0.85 - 0.99) for intra-
observer observations.
4.2 Paper II
DCE MRI at rest was performed in 63 patients in the subacute and chronic phase 
after reperfused myocardial infarct. Initial upslope, enhancement at TTPn, rBF and 
kep were lower and TTP, wash-out slope and ve were higher in infarct tissue (p <
0.001 for all analyses). Infarct tissue ve decreased to 6 months (p = 0.045). At 
baseline, infarct tissue with persistent MO had even more delayed TTP, lower rBF, 
Ktrans, kep and enhancement at TTPn and delayed contrast arrival (p < 0.008 for 
pairwise analyses). Higher rank of qualitative enhancement stratification correlated 
to larger infarcts (p < 0.001).
CRUUHODWLRQIRU02FODVVLILFDWLRQEHWZHHQREVHUYHUVZDVPRGHUDWHț = 0.5, p <
0.001). Of the 54 patients, classification was decided by consent for 25 individuals. 
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Of these, 15 were reclassified. Presence of MO changed for 7 individuals. 
Differences and conclusions of the material were not affected by reclassification.
4.3 Paper III
In a total of 38 patients, LGE cardiac MRI identified transmural infarction in 27 
patients, with a mean infarct size of 36 ± 25 g. Peak systolic İL correlated to infarct 
mass at the global level (r = 0.84, p < 0.01). A İL cut-off value of -15 % identified 
infarction with 83 % sensitivity and 93 % specificity at the global level, and 76 %
and 95 % at the territorial level. A İL cut-off value of -13 % identified infarction 
with 80 % sensitivity and 83 % specificity at the segmental level. Global infarct mass 
also correlated to wall motion score index (r = 0.70, p < 0.01), and to LVEF by 
cardiac MRI or echocardiography (r = -0.71 and -0.58, respectively; both p < 0.01). 
Assessment of early stretch and PSSI did not provide additional information by 
multivariate regression analysis.
Reliability analyses of İL UHYHDOHGD&URQEDFK¶VĮRIIRULQWHU-observer, and 
0.95 for intra-observer variation at the global level, 0.92 and 0.97 at the territorial 
level and 0.81 and 0.92 at the segmental level.
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5 Discussion
5.1 Myocardial infarct
5.1.1 Paper I
Results from paper I did not support any favorable outcome for patients treated with 
mBMC injection after myocardial infarct. This was a confirmation of earlier 
findings; primary endpoints from the ASTAMI trial, an exercise study and a three 
years outcome study all had similar development for the two treatment groups129-131.
Nevertheless, subtle differences were found. Infarct size as assessed with LGE and 
İC as assessed with tagging MRI developed beneficially for the control group. The 
first finding was in contrast to the main study, in which infarct size development did 
not differ between the two groups. Additionally, İC development differed from 
studies on regional function on the complete ASTAMI population as performed with 
echocardiography132. Correlation between İC and LGE was confirmed. A substudy 
on transmurally infarcted segments was performed for comparison with the results of 
Herbots et al.133, but our results did not confirm their finding of a more beneficial 
mBMC effect in this group.
Thus, we did not conclude that the developmental difference between treatment 
groups was relevant for the complete population of the ASTAMI study. One possible 
explanation was influence from a non-significant difference in infarct size between 
treatment groups at baseline MRI. Even though infarct size reduction is larger the 
first week after the acute incident, some volume reduction is expected at a later 
stage134;135, and functional development correlates strongly to LGE. Myocardial 
edema was not assessed, and this factor could act as an undetected confounder. 
More important, our findings confirmed a potential for regional and summarized 
regional analyses to detect subtle differences in development not found by global LV 
analysis, as assessed by biplane LVEF with cine MRI in this paper. Since 
development of methods for regional movement imaging and analysis by MRI, the 
method has shown a potential for the detailed characterization of wall movement 
disorders of various origin136-139, and recently, different developmental İC for infarcts 
with or without edema and hemorrhage has been revealed140.
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The measurements of LV twist revealed low values for the basal/apical rotational 
movement. Without healthy controls for comparison, we considered the measured 
values of infarcted ventricles to be in accordance with other studies with reduced LV 
twist after myocardial infarct. Reduced twist or apical torsion has been considered a 
sensitive and fast method for the diagnosis of myocardial tissue disease141, but there 
are different findings whether reduced torsion regains after infarct. Our interval 
measurements were stable. However, the examined group of patients was small, and 
mean LVEF was not severely reduced compared to other studies. Difference may be 
revealed with larger study group and/or larger population diversity. 
5.1.2 Paper II
Perfusion assessment of paper II was comprehensive, with semi-quantitative 
measurement of descriptive enhancement and kinetic parameters combined with 
qualitative analyses. We sampled a spectrum of analyses of tissue parameters in 
order to describe a variety of circulatory features of infarct tissue. Figure 4 repeats a 
simplified scheme illustrating the relationship between the dynamic enhancement 
parameters and the kinetic parameters. 
From the semi-quantitative parameters we largely confirmed the well-known 
decrease of perfusion in infarct tissue compared to non-infarcted tissue142-144. This 
decrease characterizes both subacute and chronic infarcts, and is apparent in visual 
analyses as well, with first pass hypoenhancement for most of the infarcts. Infarct 
tissue hypoenhancement was stable over the time interval, leading to the conclusion 
that scar tissue is hypoperfused during first pass compared to myocardium.
Ktrans was not significantly changed in infarct tissue. This finding was in contrast to 
an earlier report145, possibly resulting from setup differences with reperfused infarcts 
examined subacutely and not acutely. Ktrans is closely related to flow (F) and the PS
product. Thus, an independent flow measurement was needed and rBF was
calculated from the residue curve. As suggested in paper II, the explanation for Ktrans
and rBF developing differently could be an increase of the PS product in subacute 
infarct tissue. Another possibility is masked difference of Ktrans (as a type II fault), 
due to variability. Refined studies with more precise quantification and a sufficient 
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study population at relevant intervals may even better characterize tissue changes 
and mechanisms of repair over time after myocardial infarct.
Figure 4: Relationship between enhancement and kinetic parameters
Simplified scheme of the relationship between tissue characteristics, descriptive 
enhancement parameters and kinetic parameters. Arrows illustrate influence. Yellow 
figures illustrate parameters directly measured or calculated in paper II.
Qualitative and semi-quantitative analyses were combined, and the relative 
calculation of enhancement and kinetic parameters revealed added information on 
microvascular changes of the damaged myocardium. Infarct tissue in individuals 
with persistent MO had an even more pronounced decrease of perfusion compared to 
infarcted tissue with lower enhancement score. The study in paper III was not 
designed to detect whether there was a continuity of flow degradation in infarct 
tissue, with the central core MO at the extreme, or whether there might be a defined 
cut-off level of reduced flow at MO. Time point for diagnosing MO was probably 
not ideal29;33, and the ROI sampling of tissue was large, compared to the small areas 
of MO in the infarct.
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Furthermore, contrast agent arrival was delayed in the persistent MO group. Based 
on an experimental animal study, we explained delayed arrival with the possibility 
for collateral flow146, although a component of microvessel stenosis was also 
possible. In the experimental animal study, epicardial arteries were gradually 
occluded, stimulating collateral circulation from distant coronary territories. In paper 
II, pathological mechanisms are believed to originate on the microvascular level in 
the no-reflow territory. More detailed studies at relevant time intervals on the 
microvasculatory situation are needed to characterize these mechanisms. 
5.1.3 Paper III
The main outcome of paper III was the good correlation between detailed regional 
echocardiography and infarct size and transmurality. İL as assessed with 2D-STE 
was achieved from 90 % of all segments from longitudinal grayscale 
echocardiography. When defining cut-off levels, severly reduced İL identified 
transmurally infarcted segments, severely infarcted coronary territories, or LVs with 
large infarcts. The global index of İL seemed to perform better for sensitivity and 
specificity, with the highest AUC of the ROC-analyses. Two possible explanations to 
the latter are the potentially favorable effect from averaging of noise, and
independency from anatomical assignment differences across modalities when global 
indices are calculated. Visual assessment leading to WMSI similarly detected severe 
infarction. This finding both confirmed the strong relationship between infarct 
affection and myocardial function in this population, and the possible strength for 
regional wall motion analyses in the detailed characterization of the infarcted LV.
Two other parameters, PSSI and early stretch were calculated from 2D-STE. Of 
these, correlation with infarct size was higher for PSSI. This parameter is virtually 
different from systolic İL, characterizing another mechanical property of diseased 
myocardium. Two mechanisms can explain the shortening of infarct tissue after end 
systole; an active but impaired sarcomer shortening in cardiomyocytes, or passive 
recoil which shortens tissue when wall tension falls. The last mechanism is to a 
larger extent believed to be present in scar tissue147. The ability of PSSI to identify 
large and transmural infarct in this population gave no clue to the distinction between 
these two mechanisms, but confirmed presence of the phenomenon. Furthermore, it 
indicated that quality of 2D-STE was preserved during diastole. 
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From multivariate analysis we found that global İL correlated independently with 
infarct size, but not with LVEF. This was an interesting finding, considering the 
relation between global İL and LVEF; both characterizing LV contraction. In this 
paper, the different diagnostic tests were not directly compared against each other 
with any superiority or non-inferiority test. A later publication revealed better 
performance for global İL than LVEF as examined by echocardiography in the 
identification of different infarct sizes, and better performance for global İL than 
WMSI in the identification of small and medium-sized infarcts148.
For the ROC analyses infarct areas were categorized into transmural/not transmural, 
or large/not large in order to construct dichotomous variables and to quantify 
sensitivity and specificity. In turn, this led to the definition of cut-off levels for 
significant pathology of İL as measured by 2D-STE. Where to set cut-off levels for 
the definition of pathology is dependent on the clinical setting. We studied a 
predefined population, with high incidence of pathology. The important part in this 
setting was to avoid overlooking decreased myocardial function and large infarcts, 
thus sensitivity was more important than specificity. Still, the results illuminate a 
challenge in the definition of a normal level. Non-infarcted tissue in the diseased 
group had lower İL than myocardial tissue in healthy controls. The cut-off value 
chosen identified large infarcts, and for this purpose also remote tissue of patients 
was included among normal myocardium. This may not always be the best solution;
concerning the possibility that remote remodeling affects clinical parameters of 
interest in other settings.
5.2 Patient selection
In the present work, all the investigated patients had STEMI treated by PCI. All were 
between 40 and 75 years old and most had evidence of anterior wall infarct. In paper 
III, the patient group was more heterogeneous with some patients with lateral and 
inferior wall infarcts. However, the patient groups were relatively similar regarding 
age, lower representation of women, mean infarct size and cardiac function (Table 
1).
The use of MRI in itself introduces a potential for skewed recruitment of patients to 
research. First, no incompatible devices are allowed; including several monitoring 
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devices for critically ill patients, LV assisting devices, and most ICDs and 
pacemakers. Second, cardiovascular monitoring is challenging in the MR suite, and 
unstable patients may worsen hemodynamically solely from the laying still on the 
back through a complete examination. Third, there are still substantial challenges 
when examining the heart of patients with complex arrhythmia. Forth, the use of Gd
is precluded in patients with seriously decreased renal function, although the 
relationship between nephrogenic systemic fibrosis and Gd was unknown at the time 
of patient inclusion for these three studies.
Care must therefore be taken to generalize findings from these studies.
5.3 Study design
5.3.1 Paper I
As a substudy of the larger ASTAMI study, paper I was an open-labeled, randomized 
prospective study. The main aim was similar to the aim of the ASTAMI trial; effect 
from treatment with intracoronary injection of mBMC, for this paper assessed with 
the secondary endpoints İC and LV twist. The ASTAMI study in itself was designed 
to have sufficient power to detect a difference of 5 % points of LVEF as examined 
by single-photon-emission computed tomography. For paper I power was assumed 
inferior because of low inclusion number.
Reduced inclusion compared to the main ASTAMI study was caused by the 
shortened inclusion time interval. Characteristics of sub populations may be different 
from the total population due to sample error, but no known systematic error had 
been introduced. The distribution between treatment and control was quite even, and 
there was no significant difference in baseline characteristics between treatment
groups. 
5.3.2 Paper II
Although another substudy of the ASTAMI study, design and purpose of paper II
differed. The objects studied were infarct tissue versus non-infarcted myocardium, 
with an interval study on infarct tissue. Treatment groups with or without 
intracoronary mBMC injection were merged, and the interventional aspect of the 
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ASTAMI study was not taken into account. Thus, this paper is a prospective, 
comparative observational study.
Merge of the 2 treatment groups was based on the presumption that neither infarcted 
nor non-infarcted myocardial tissue differed between the groups. This was supported 
by earlier reports from the ASTAMI study129-132;149. All perfusion and enhancement 
parameters were controlled for treatment effect without detecting difference, and all 
correlation analyses were performed with treatment randomization as covariate 
without any correlation or influence on other correlation. We concluded that the 
presumption was justified.
5.3.3 Paper III
The purpose of this study was the exploration of different non-invasive diagnostic 
tests for the assessment of LV function. A cross-sectional design was considered 
adequate.
Diagnostic methods are often tested without the knowledge of the true value of the 
parameter to be measured. Infarct size characterized with LGE served the role as 
reference method; no gold standard for regional LV function was chosen. We 
believed chronic myocardial infarct to be the sole explanation of myocardial function
reduction. This assumption was indirectly, but only partly controlled for by the LGE 
assessment126.
ROC-curves of the diagnostic tests and correlation between LGE and the different 
test methods were considered suitable graphical summaries to illustrate the 
performance of diagnostic tests150. Difference between test scores was not explored, 
and this study was not designed to conclude that any of the diagnostic tests were
superior or inferior to the others151.
5.4 Reliability
Reliability refers to parameter consistency, depending on precision and accuracy.
5.4.1 Infarct detection and extent
For all studies, the correct diagnosis of infarct size, transmurality and location with 
LGE was crucial. In paper I infarct size was one of the endpoints reported, and the 
segments were subgrouped according to transmurality classification. In paper II the 
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interpretation of infarct and non-infarct tissue decided ROI placement for infarct and 
non-infarct TIC calculation. Infarct size was an important covariate, and LGE was 
even important in the qualitative assessment of enhancement groups. In paper III 
segmental, territorial and global infarct size and infarct percent were the reference 
measurements for the diagnostic tools to be tested.  
Method for LGE performance and image analysis has proven robust152, and standard 
procedures were well proven and according to international guidelines. Contrast 
agent dosage recommendations vary between 0.1 – 0.2 mmol Gd/kg120;125;152. For the 
higher dosage, one has to wait sufficiently long after contrast agent injection before 
imaging in order to avoid masking of subendocardial high intensity due to high blood 
pool intensity125. Inversion time has to be adjusted to null normal myocardium signal 
intensity, irrespective of dosage and time point after contrast agent injection.
Short axis views covering the complete LV were utilized for manual LGE 
delineation. When infarct border was dubious, cross-correlation to long axis images 
was performed. When still in doubt a cut-off value of neighboring myocardium 
signal intensity + 2 SD for infarct tissue was utilized, as reported in paper III. This 
may look controversial, when regarding a recommendation of + 5 SD as a threshold, 
concluding that + 2 SD was associated with overestimation of effective infarct 
size153. In this respect, it is important to notice that the recommendation was valid for 
automated quantification software. To date, choice of threshold level is still not 
established120;152. Infarcts of relatively lower intensity do exist 154. For paper I - III
manual analysis was performed. This is still regarded the most precise method, and 
for such the threshold is of less controversy120. In our experience, local signal 
intensity difference between viable and infarcted tissue is far exceeding the + 2 SD 
threshold, also confirmed by an early report on LGE imaging and analysis42.
Infarct transmurality is directly derived from infarct size assessment; dependent on 
the reading of LGE imaging with a precise anatomical assignment. We defined 
transmurality level based on percent scar. However, definition of transmurally 
infarcted segments differed two of the papers; 75 % in paper I and 50 % in paper 
III. In paper I the threshold of 75 % was chosen in order to compare results to the 
publication by Herbots et al.133. This threshold has been shown to be of clinical 
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interest42. The threshold of 50 % in paper III was similar to earlier publications 
exploring regional İ and strain rate after myocardial infarct155;156.
Infarct assessment in these studies relied on a well-proven method, the correct 
delineation of hyperenhancing myocardium and robust anatomical assignment also 
corresponding to anatomical assignment of the other imaging methods. For these 
studies, infarct tissue was examined in the subacute and chronic stages. Infarct tissue 
was clearly hyperenhancing, and earlier phase infarct assessment would have 
brought more confounding edema. Correlation to regional function was excellent.
5.4.2 Left ventricular volumes and ejection fraction
LV volumes, as assessed by cine MRI for paper I and III were calculated from two 
long axis projections using the “biplane ellipsoid formula”. At the time for study 
design; this method was regarded fast and sufficiently accurate for volume 
measurements90;92;93. The formula is based on the understanding of the LV as a 
regular 3D ellipsoid, each axis with different radius. Volume is derived from the 
equation
l
AAV 
 S3
8 21
(6)
where A1 and A2 are the areas of the ventricular cavity in each long axis projection,
and l is the LV long axis. The main objections to the formula are the principal 
objection to the presumption of a symmetric 3D object, secondarily that the model 
lacks adjustment for irregular contraction, and third the fact that the cut end at the 
base is not taken into account.
Later studies and general recommendations have stressed the increased accuracy and 
decreased variability of the application of Simpson’s rule with the summing of a 
complete set of short axis slices157 although for clinical purposes a fast evaluation 
with the biplane technique may be considered acceptable120.
Change from spoiled GRE to bSSFP cine in our institution affected cine sequences 
of papers I and III. Measurements were known to vary between these two 
acquisitions83;84. Care was taken to secure that all patients of the ASTAMI study 
were examined with paired either spoiled GRE or bSSFP, this was relevant for paper 
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I. In paper III, both methods were represented in the study population. Inter- and 
intraobserver variability assessment of the ASTAMI study revealed that variability 
for spoiled GRE acquisition was larger than for bSSFP (Figure 5)158. Even though 
variability assessment was performed only from a random sample among all 
ASTAMI patients, the calculations were performed in the same period of time, and 
we believe the numbers to be relevant for the examinations of paper I and III.
Figure 5: Inter-observer variability assessment for the ASTAMI study 
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Bland Altman plots from inter-observer variability assessment for LVEF in the 
ASTAMI study Left: spoiled GRE sequence (FLASH), right: bSSFP (trueFISP)
The method chosen for volume calculation and the observed variability may have 
masked differences between groups in paper I or diminished precision in paper III. 
5.4.3 Strain and torsion
In papers I and III good correlation between regional İ and LGE was confirmed.
However, İ is known to be load dependent, and this may be part of the explanation 
for decreased İ in remote areas after infarct159-161. In these papers, all patients were 
hemodynamically stable, and results are not believed to be severely influenced from 
individual variation of load.
5.4.3.1 Tagging MRI
For HARP analysis of tagging MRI, inter- and intra-observer assessment has been 
performed as a part of the large Multi-Ethnic Study of Atherosclerosis108. As in paper 
I, agreement was good. The authors reported that mid-wall İC was more stable, with 
best agreement for peak İC. Identifiable tag fading made diastolic analysis less 
stable. As stated above, the CSPAMM technique enables more stable tags; this has 
51
later been utilized by a study on the early post-systolic phase after myocardial 
infarct162.
Software HARP version 1.0 was used for analysis. Mid-wall Lagrangian İC was 
calculated from the deformation curves in 24 points in each slice. The software 
version was semi-automatic with limited ability for the correction of erroneous 
tracking (“tag jumping”). Thus, tag noise prolonged analysis time and caused 
extreme İC values of some single points. This was managed with the exclusion of İC
values > 10 % and < -30 %. Figure 6 illustrates systolic tag jumping of one 
registration point, and İC curves before and after exclusion. Most often tag jumping 
led to elongation of the deformation line. Thus, noise mainly reduces İC amplitude, 
partially corrected by exclusion. More complex noise involving several neighboring 
points led to exclusion of segments, and even territories.
Torsion analyses seemed more robust. Data were less characterized by noise, and no 
exclusion was performed. Torsion analysis agreement was good. No control group 
was examined. In paper I absolute torsion measurement in infarcted hearts were 
lower than in normal hearts reported in other studies, and were considered 
reduced163;164. We were not able to confirm any longitudinal alteration of decreased
torsion after infarction in paper I.
Tagging results revealed İC differences in the study population. The differences 
correlated well with infarct size and infarct size development. Sample size was small, 
and noise led to exclusions. However, agreement was good, and thus, results were 
considered reliable.
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Figure 6: Tag jumping and exclusion of extreme values
End systolic (7th) frame (left) from Harp analysis of 
a mid-ventricular slice without LGE. Note tag 
jumping of one point, causing elongation of two 
deformation lines with the resulting positive İC of 
the anterolateral segment (middle). İC curves 
(bottom) after exclusion of two extreme values.
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5.4.3.2 Two-dimensional speckle tracking echocardiography
Proper 2D-STE registration is dependent on quality echocardiography with good 
delineation of myocardium, lack of reverberations and a sufficient frame rate. For 
paper III, 90 % of all LV segments were included for İL analysis, and variability 
assessment from repeated echocardiography showed good correlation for İL
assessment. In other studies, variability between observers has varied between 
moderate and good163;164, though in one study reproducibility for İL scored even 
better than tagging MRI165.
For paper III İL, PSSI and early stretch were examined on the segment level, 
territorial level and global LV level. Performance for the identification of severe 
infarct was better for global examination, probably as a result from noise averaging 
and independence from anatomical assignment. We have seen even better correlation 
to segmental infarct affection in a recent 3D area İ study, and part of this 
improvement may be the easier anatomical assignment166. The territorial indices may 
seem artificial, considering the large inter-individual variation in coronary perfusion 
territories. However, for clinical purposes this assessment is relevant with the 
potential not only to diagnose typical infarct distribution, but also to discriminate 
severe from less severe infarct affection. The averaging of global İL is logical, 
providing a parameter for the global LV function. The averaging of PSSI in fact 
provided a parameter with almost similar potential for severe infarct identification. 
Early stretch was a less sensitive marker of severe infarct affection in paper III.
The main impact of paper III was the illustration of reliability of İL as a parameter 
with potential for the assessment of severe regional myocardial affection. Although 
noise may be a challenge, and some exclusion was made, scores were good
especially on the global level, with good correlation for repeated echocardiography 
examination. This is in accordance with later studies, which have confirmed good 
performance of İL as assessed by 2D-STE167-170. A recent study has even indicated 
superior performance of İL compared to more conventional echocardiographic 
methods171.
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5.4.4 Myocardial perfusion
Absolute perfusion quantification by MRI has been correlated to labeled blood cells 
or injected microspheres in animal models 158;172-174 and with human positron 
emission tomography studies118;175;176. Correlation is moderate to good, and 
methodological refinement is probably needed. An inter-study approach revealed a 
coefficient of variation > 25 % for myocardial perfusion measurement at stress177.
The absolute perfusion quantification is among other details dependent on a reliable 
measurement of the arterial input and an appropriate mathematical model for the 
deconvolution of tissue intensity measurements to the input function. 
The main challenge for a reliable AIF measurement is the non-linearity between 
signal intensity and contrast agent concentration178;179. Different contrast agent 
infusion regimes have been tested, including the infusion of smaller dosage. Contrast 
agent dosage has to be < 0.03 mmol Gd/kg if not to exceed non-linearity between 
AIF and contrast concentration of more than 10 – 15 %. Underestimation of arterial 
contrast agent concentration will in turn cause overestimation of tissue perfusion.
The process of deconvolution is very sensitive to noisy data, introducing a risk for 
large resulting differences180. Different modeling has been tested to obtain 
physiological solutions to the calculations, among which the model independent
analysis seems to the most stable181.
Enhancement parameters directly measured from TICs are not dependent on 
modeling, and some parameters are closely related to flow. However, these 
parameters vary with hemodynamic and infusion variations182. Normalizing against 
the AIF stabilizes this variation, but for some of the parameters the non-linearity of 
the AIF becomes a challenge. In paper II, we believe the variation to be partially 
controlled by standardized infusion regimes in hemodynamically stable patients. An 
attempt to normalize tissue enhancement parameters to AIF did not reduce 
variability. 
The combination with visual assessment of perfusion sequences demanded a 
sufficiently high contrast agent dosage, and absolute perfusion measurement was 
precluded due to T2* effects. Thus, we presented relative and semi-quantitative 
measurements. Quality of data was reduced by the unforeseen alteration of perfusion 
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sequence due to magnet upgrade. Table 3 lists some different parameters before and 
after upgrade. 
Table 3: Perfusion sequence parameters before and after MR unit upgrade
Flip 
angle TE TI
Spatial 
resolution
Slice 
thickness Stacks
Temporal 
resolution
Before 
upgrade Û 1.2 ms 300 ms 1.17 mm 10 mm 60
2 heart 
beats
After 
upgrade Û
0.96 
ms 100 ms
1.36 – 1.52 
mm 8 mm 120
1 heart 
beat
TE: echo time, TI: inversion time
Among these parameters, an inversion time of 300 ms might be longer than 
desired183. Shortening the inversion time reduces the non-linearity T2* effect, but 
signal to noise ratio may be reduced. The alteration of this parameter may have 
changed the dynamic range of the perfusion sequence. In order to correct for this 
error, only paired examinations either before or after upgrade were included. Patients 
examined with different perfusion sequences at the two time points were excluded 
from the material, reducing sample size and possibly power. For correlation analyses, 
perfusion sequence was included as a covariate parameter.
Paired comparison was performed between infarct and normal tissue. Possibly the 
term remote tissue would have been more appropriate. Reduced contractile function 
in remote myocardium after AMI has been shown, explained by dilatation and/or
loading conditions138;161;184. The early changes in remote myocardium after AMI are 
not completely understood, and a recent study not only revealed reduced contraction,
but also T1 shortening in remote myocardium, additionally coupled to the finding of
deposition of fibrous tissue and possibly inflammatory mechanisms185. Reduced 
perfusion has not been considered part of changes of remote myocardium. On the 
other hand, any alteration of extracellular matrix should influence wash-out, kep and 
ve.
Interval examination of infarct tissue confirmed presence of reduced perfusion and 
increased ve in chronic infarct tissue, as compared to normal myocardium. Over time, 
ve decreased without change of other perfusion parameters. This was in accordance  
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with studies on infarct tissue with estimation of the myocardial tissue-blood partition 
coefficient124;186, whereas longitudinal studies on perfusion are scarce. In normal 
subjects and even in a group of subjects with coronary disease, inter study variability 
of DCE MRI has been measured to be in the magnitude of variability of perfusion 
studies with positron emission tomography187-189. Physiological variation,
measurement variation and variation from calculation may be present, and the 
implication of longitudinal differences is not completely assessed190.
To sum up, the quantification of perfusion in this study was semi-quantitative and 
measurement levels cannot be directly compared to results from other studies. 
Several design challenges exist, but altogether, the main consequence was probably 
masking of difference. The measured differences between infarcted and non-
infarcted tissue are believed to be reliable.
5.4.5 Microvascular obstruction
The qualitative assessment of infarct tissue enhancement was performed as a 
combined analysis of early phase perfusion imaging and LGE. Such qualitative 
assessment is prone to subjectivity. In order to ensure reliability, clear criteria for 
identifying MO were defined. Analysis was performed by two independent 
observers, and for disagreement qualitative enhancement grouping was settled by 
consent. This procedure proved necessary with moderate correlation between 
observers.
As stated above both subacute infarct and scar tissue are generally hypoperfused 
during first pass compared to non-infarcted myocardium. This was confirmed for a 
great majority of the infarcts with relative hypoenhancement subacutely, as an 
ordinary finding after myocardial infarct. Measurements revealed substantial 
differences between enhancement groups, with a more severe perfusion reduction in 
tissue with persistent MO than with first pass hypoenhancement only. Qualitative 
visualization of the difference is probably dependent on a series of technical 
parameters including sequence parameters, in-plane resolution and contrast agent 
dosage. However, the finding emphasizes the difference between first pass 
hypoperfusion and MO, and the term MO should be reserved for infarct tissue with a 
57
hypoenhancing zone at a later stage after contrast agent infusion than at first 
pass28;120.
Our observations led us to believe there is continuity between MO and persistent 
MO. The area of persistent MO was invariably a lesser part of the MO area; but on 
the other hand the finding of MO did not always lead to a finding of persistent MO. 
This is consistent with previous descriptions of persistent MO31;33. Although the 
natural time course for MO is not clarified, we suspect there is a similar temporal 
continuity, with the final resolution of the central core MO occurring from days to 
weeks after the acute incident. In paper III we did not correlate MO to prognostic 
factors. The different enhancement groups were small and adverse events were 
scarce. Presence of MO and size of the present MO correlate to infarct size, and in 
some studies MO has shown independent impact on prognosis28;31-33. One serial 
study suggested a correlation between later resolution of the central core MO and 
adverse remodelling33. However, the complete relation between MO and prognosis 
remains to be clarified; whether MO size, classification to MO or persistent MO,
time point for MO resolution or the independent contribution from infarct size are 
most important.
Correlation between enhancement groups and semi-quantitative measurements were 
not influenced by re-grouping after consent between observers. Thus, findings were 
considered reliable. The comprehensive analyses emphasized the need for more 
studies on early and late microvasculatory changes of acute infarct.
5.5 Validity
The goal in myocardial infarct research is to reduce mortality and morbidity of the 
disease. Consequently, the relevant primary endpoints for this research are death, 
reinfarction and symptoms from cardiac disease. However, such research is in the 
need for large sample sizes and long follow-up, associated with high cost and risk for 
missing data and noncompliance. Medical imaging and other diagnostic tests 
therefore may provide surrogate endpoints, in order to overcome these shortcomings; 
at least partially. Surrogate endpoints are biomarkers of disease, expected to predict 
clinical benefit or harm. Advantages of surrogate endpoints are the potential for 
studies with smaller sample size, shorter follow-up and to a larger extent restriction 
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to one center trials. This is caused by the endpoint variable to reflect biological 
changes with lower threshold than the primary endpoints. Biomarkers can play the 
role as surrogate endpoints provided they are reliable and valid.
For a biomarker to be valid, change of the biomarker has to be relevant for outcome. 
Relationship between morbidity or mortality and the surrogate endpoint has to be 
biologically plausible. The prognostic value for the surrogate has to be demonstrated 
in epidemiological studies. And finally, there has to be evidence that treatment effect 
influencing the surrogate corresponds to clinically relevant effects191. Even though 
validity is plausible, evidence lacks for this last point for many parameters. 
LVEF is a valid surrogate endpoint. Infarct size assessed with LGE is reliable, and is 
believed valid, although the proving for treatment effect on LGE to influence clinical 
relevant effects still lacks. Assessment of regional dysfunction is sensitive and has 
proven reliable. However, validity for minor differences not detectable with 
traditional global assessment is until now more questionable. For perfusion imaging 
MO is thought to be a valid parameter, but the complete assessment of reliability is 
missing191.
A recent meta-analysis on surrogate studies versus primary endpoint studies, found a 
difference between the two groups. Trials reporting surrogate endpoint were more 
likely to report larger treatment effects than the other group of trials reporting final 
patient relevant outcomes192. Probably this partly reflects the main advantages of 
surrogate endpoints as sensitive parameters in research. Nevertheless, effects on 
surrogate endpoints have to be considered with caution.
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6 Conclusions
6.1 Paper I
LGE and İC quite similarly demonstrate subtle differences between the mBMC and 
control groups. No beneficial regional or global effect on myocardial function is 
detected after mBMC injection.
6.2 Paper II
Reperfused infarct tissue has reduced perfusion and increased ve compared to normal 
tissue, and infarct tissue ve decreases with scarring. The presence of persistent MO 
results in delayed contrast arrival time and an even more pronounced perfusion 
reduction.
6.3 Paper III
Peak systolic İL by 2D-STE correlates to the infarct mass assessed by LGE at a 
global level, and separates infarcted from non-infarcted tissue. İL is an excellent 
predictor of myocardial infarct size and transmurality in chronic ischemic heart 
disease.
6.4 Conclusion of the Thesis
MRI is a valuable tool for the detection of subtle, regional differences in myocardial 
infarct tissue. Comprehensive MRI combining relevant pulse sequences has potential 
to illuminate complex patophysiological mechanisms. Cardiac MRI may be used as 
reference for the validation of new diagnostic tests characterizing the infarcted heart.
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7 Future perspectives
Dynamic MRI is a powerful diagnostic tool for myocardial infarction, and carries
valuable surrogate endpoints for research on ischemic heart disease. Speckle tracking 
echocardiography may have similar power in the assessment of myocardial function.
LV volumes and LVEF as assessed with MRI are reliable and valid surrogate 
endpoints for further interventional cardiac research. Regional and global function 
assessed with either echocardiography or MRI has the potential for even more 
precise characterization of the LV. When proven valid, this improved 
characterization may refine clinical research. Infarct assessment with LGE is another 
reliable surrogate endpoint for cardiac research, although complete consensus for 
image analysis is still missing120.
There is considerable challenge concerning the absolute quantification of myocardial 
perfusion MRI. Positron emission tomography is the current gold standard for flow 
measurement in the myocardium, and further validation and refinement of the 
method is needed. Method for the assessment of MO may still develop, in order to 
come closer to consensus for contrast agent administration and time after injection 
for ideal read-out. Additionally, more knowledge about the natural course of MO is 
needed191.
Since the publication of paper I - III, technical evolution and refinement of methods 
have continued. New methods have been introduced, reliability has for some been 
confirmed. T2 imaging may have a role in assessment of AMI for salvage 
examination193;194. T1 mapping has been introduced and seems to have great 
potential in the characterization of diseased myocardium, and cardiac proton 
spectroscopy has entered the field of clinical research185;195. However, there is still 
need to make evidence for a majority of the tools as reliable and valid surrogate 
endpoints for trials191. These new applications already here provide potentials for 
more detailed assessment of myocardial infarct disease as to increase understanding 
of necrosis, reperfusion, microvascular damage and repair. MRI and echo combined
with other modalities through hybrid solutions and image fusion are other 
perspectives for comprehensive research and increased understanding122;185;195.
At last, we have to keep in mind that surrogate endpoints are not primary.
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Abstract
Background: Trials have brought diverse results of bone marrow stem cell treatment in necrotic myocardium. This
substudy from the Autologous Stem Cell Transplantation in Acute Myocardial Infarction trial (ASTAMI) explored
global and regional myocardial function after intracoronary injection of autologous mononuclear bone marrow
cells (mBMC) in acute anterior wall myocardial infarction treated with percutaneous coronary intervention.
Methods: Cardiovascular magnetic resonance (CMR) tagging was performed 2-3 weeks and 6 months after
revascularization in 15 patients treated with intracoronary stem cell injection (mBMC group) and in 13 controls
without sham injection. Global and regional left ventricular (LV) strain and LV twist were correlated to cine CMR
and late gadolinium enhancement (LGE).
Results: In the control group myocardial function as measured by strain improved for the global LV (6 months:
-13.1 ± 2.4 versus 2-3 weeks: -11.9 ± 3.4%, p = 0.014) and for the infarct zone (-11.8 ± 3.0 versus -9.3 ± 4.1%, p =
0.001), and significantly more than in the mBMC group (inter-group p = 0.027 for global strain, respectively p =
0.009 for infarct zone strain). LV infarct mass decreased (35.7 ± 20.4 versus 45.7 ± 29.5 g, p = 0.024), also
significantly more pronounced than the mBMC group (inter-group p = 0.034). LV twist was initially low and
remained unchanged irrespective of therapy.
Conclusions: LGE and strain findings quite similarly demonstrate subtle differences between the mBMC and
control groups. Intracoronary injection of autologous mBMC did not strengthen regional or global myocardial
function in this substudy.
Trial registration: ClinicalTrials.gov: NCT00199823
Background
Different studies have brought diverse results on the
effects of cell therapy in acute myocardial infarction.
Effect measures have included clinical parameters and
measurements of global left ventricular (LV) function
obtained through a spectrum of methods [1-6]. Some
groups have explored regional left ventricular function
as evaluated by wall motion or wall thickening assessed
from cardiovascular magnetic resonance (CMR) or myo-
cardial remodeling assessed from strain echocardiogra-
phy [4,7-10]. Treatment for large myocardial infarctions
is considered more challenging due to risk for LV dilata-
tion and progressive ejection fraction (EF) reduction,
and in three of the studies subgroup analyses have indi-
cated a more substantial beneficial effect from stem cell
therapy in large infarctions or in hearts with low LV EF
[8,9,11]. Myocardial strain calculated from CMR tagging
is currently regarded as the non-invasive gold standard
for assessment of regional function. However, limited
availability and analysis effort seem to reduce the overall
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use of the method [12,13]. In this substudy of the Autolo-
gous Stem Cell Transplantation in Acute Myocardial
Infarction trial (ASTAMI) [2], we calculated LV circum-
ferential strain and twist from short axis grid CMR tag-
ging obtained on 28 patients first at 2-3 weeks and then
subsequently 6 months after the infarction. We examined
whether intracoronary injection of autologous mononuc-
lear bone marrow cells (mBMC) influenced regional
myocardial function or LV twist. In addition, we aimed
to explore the potentials for tagging analysis to detect
more subtle changes in myocardial function undetectable
by other examination techniques in routine use.
Methods
Study group
Methods and techniques used in the ASTAMI trial have
been reported in detail previously [2]. Briefly, 100 patients
with acute left anterior descending artery (LAD) myocar-
dial infarction were randomized to either intracoronary
injection of autologous mBMC (mBMC group) or control
with no sham injection after successful revascularization.
mBMC injection was performed 4-8 days (mean 6 days)
after percutaneous coronary intervention (PCI). Baseline
CMR was performed after 2-3 weeks (18.8 ± 3.8 days)
after myocardial infarction and was repeated after
6 months. For this substudy, the CMR protocol included
short axis grid tagging sequences in addition to cine
images and post contrast late gadolinium enhancement
(LGE). The patients were a consecutive series of the last
28 patients included in ASTAMI who either received
mBMC per protocol (n = 15) or belonged to the control
group (n = 13). The study complies with the Declaration
of Helsinki, and the protocol was approved by the regional
committee for research ethics. All patients gave written,
informed consent.
Cardiac Magnetic Resonance
Cine images, tagging sequences and late enhancement
images were acquired in the same image session with
1.5 tesla units (Magnetom Vision Plus or Magnetom
Sonata, Siemens, Erlangen, Germany) with a phased
array body coil.
Two cine long axis projections of the left ventricle were
acquired with either a breath-hold segmented spoiled
gradient echo sequence, fast low angle shot (FLASH) or a
breath-hold segmented balanced gradient echo sequence,
fast imaging with steady-state free precession (trueFISP).
Each patient had either paired FLASH or paired trueFISP
examinations. Temporal resolution was 50 ms or less and
slice thickness was 6 mm.
Tagged CMR of the left ventricle was obtained with a
FLASH sequence. Three short axis levels were standar-
dized with the basal level just apical to the mitral ring at
end-systole, the mid-ventricular level on the mid-point
of the left ventricular long axis, and apical level just
basal to the level of luminal closure at end-systole.
Orthogonal tags in a grid pattern were parallel or per-
pendicular to the 2-chamber long axis plane with dis-
tance between tags of 8 mm. Temporal resolution was
less than 50 ms and slice thickness 6 or 8 mm.
Late enhancement images were obtained 10 - 20 min-
utes after intravenous injection of 0.2 mmol/kg gado-
pentetate dimeglumine (Magnevist, Schering, Berlin,
Germany) in two long axis projections corresponding to
the cine images and multiple short axis projections cov-
ering the LV with a breath-hold inversion recovery
turbo gradient echo sequence. The inversion time was
chosen to null the signal of the normal myocardium.
Slice thickness was 7 or 8 mm and increment between
slices was 10 mm.
CMR analysis
All CMR analyses were performed blinded to treatment
allocation. End diastolic volumes (EDV), end systolic
volumes (ESV) and EF were calculated according to the
biplane area-length method from the two long axis cine
projections [14].
Tagging recordings were analyzed with Harmonic
Phase Imaging (HARP version 1.0, Diagnosoft Inc, Palo
Alto, California). For each slice, 24 mid-wall points were
semi-automatically tracked, and circumferential Lagran-
gian end systolic strain was calculated from deformation
of the line between points. Each of the 24 strain mea-
surements were manually assigned to the 16 segment
model [15], and mean strain was obtained for all seg-
ments, selected LV regions and the global LV. By con-
vention negative strain indicates myocardial shortening.
Typical segmental tagging analysis of an apical slice is
illustrated in Figure 1.
Segments were excluded for further analysis if more
than half of the segment’s strain curves had been
excluded due to noise. The LV regions were excluded
for further analysis if more than half of the segments in
the region had been excluded. Global mean strain values
were excluded if more than 50% of the segments had
been excluded or if either the basal, mid-ventricular or
apical slices suffered from missing segmental data.
LV rotation data were obtained from the mid-wall
tracking also made for strain analysis in the basal and
apical slices, values given in degrees. LV twist was calcu-
lated as basal rotation subtracted from apical rotation.
Strain and twist inter- and intra-observer reproducibility
was assessed through repeated analyses of 10 randomly
chosen tagging examinations.
Late enhancement short axis slices were manually
assigned to basal, mid or apical left ventricular slices
and divided into sectors to fit the 16 segment model
[15]. Myocardial borders and the enhancing areas were
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manually delineated (PACS, Sectra, Sweden) [12,16-18].
Absolute and relative myocardial infarct volumes were
obtained for each segment. Myocardial and infarct
masses were converted from volume by multiplying by
1.05 g/ml [19].
LGE and strain data were analyzed globally and in
corresponding LV regions, based on baseline LGE find-
ings. All infarct segments in each patient were sum-
marized, denoted infarct zone. All segments without
late enhancement were denoted remote segments. Seg-
ments with more than 75% infarct were studied selec-
tively, denoted transmural infarct zone, corresponding
to the transmurally infarcted segments studied by
Herbots et al. [8].
Statistics
Categorical variables were analyzed with the chi-square
test. Continuous data are presented as mean ± standard
deviation, and in the gross material all variables for
baseline and end-point analyses approximated a normal
distribution. For comparisons between groups at base-
line two-sample t-tests were performed. Intra-group
changes were evaluated by paired sample t-tests. Devel-
opment between 2-3 weeks and 6 months was assessed
by analysis of covariance, with the baseline values used
as a covariate. Corresponding analyses were performed
on patients with lower than median EF at baseline
CMR. Owing to the relatively low number of patients
inter-group comparisons were performed with the
segmental strain
0
5
F1 F2 F3 F4 F5 F6 F7 F8 F9 F10 F11 F12 F13 F14 F15 F16
-10
-5
strain (%)
anterior wall
septum
inferior wall
lateral wall
-20
-15
frame
Figure 1 Baseline apical tagging analysis in a 49 year old male patient in the mBMC group. Upper part: The curves represent strain in the
apical segments, analyzed with HARP software from a short axis CMR tagging sequence. The vertical box represents the end systolic frame (F6).
There is almost normal function in the lateral wall, dysfunction in the inferior wall, while septum and the anterior wall are almost akinetic with
possible post-systolic contraction. Note increasing noise during diastolic frames, due to T1 relaxation of the tagged myocardium. Lower part: Left:
Short axis apical LGE image with hyperintensity in the anterior wall, septum and part of the inferior wall. Mid and right: Short axis apical end
diastolic (mid) and end systolic (right) tagging images with application of the semi-automatically traced lines from HARP software.
Circumferential mid-wall end systolic strain was calculated from deformation of the orange mid-wall line.
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non-parametric Mann-Whitney test and intra-group
change was evaluated with the Wilcoxon signed ranks
test. For tagging reproducibility two-way mixed absolute
agreement intraclass correlation analyses of global and
regional strain and twist were performed. The intraclass
correlation coefficients (ICC) are presented with 95%
confidence interval. SPSS software version 16.0 was
used. Tests were two-sided, and p-values < 0.05 were
considered statistically significant.
Results
Patient characteristics and LV measurements
Among all patients, the mean age was 58.6 ± 9.1 years,
mean time from the onset of symptoms to PCI was 234 ±
104 minutes, and the mean value for maximum creatine
kinase MB was 361 ± 136 μg per liter. The characteristics
of the patients at admission did not differ significantly
between the two groups (Table 1).
The results of volumetric, LGE, strain and twist ana-
lyses for all patients are summarized in Table 2, and
selected results for the group of patients with baseline
EF lower than median (51.9%) are summarized in Table
3. At baseline, there were no significant differences
between the groups for EF, ESV, EDV, LV mass, infarct
size, LV strain or LV twist, and there were no significant
differences in myocardial mass, infarct mass, infarct per-
cent or strain in the LV regions examined.
EDV and ESV did not change over time, but there was
a trend towards increased EF from the baseline exami-
nation to 6 months, irrespective of treatment allocation.
In the subgroup of patients with low baseline EF, EF
increased significantly (43.7 ± 7.2 to 51.9 ± 8.8%, p =
0.042) and ESV decreased significantly (114.8 ± 38.1 to
95.2 ± 43.6 ml, p = 0.043) in the control group but did
not change in the mBMC group.
Late gadolinium enhancement
Average segmental LGE at baseline is illustrated in
Figure 2a. All 448 segments in all 28 patients were
included for LGE analysis at both time points. The indivi-
dual LV infarct percent at baseline ranged from 2.2% to
50.1%. Ten patients had small (< 18%), 9 had intermedi-
ate (18-30%) and 9 had large infarcts (> 30%) [20]. A
total of 271 segments were judged as partially or comple-
tely infarcted at baseline, respectively 266 at 6 months.
The infarcts affected the basal segments of LV in 15
patients only; 14 of these had large and medium-sized
infarcts. In all but 1 patient the infarct involved at least 1
segment outside the presumed LAD supplying territory
[15]. In the mid-ventricular part of LV, there was LGE in
the inferior septum in 26 patients and in the anterior lat-
eral wall in 23 patients. In the apical part the inferior and
lateral segments were infarcted in 27 and 24 patients,
respectively. LV infarct mass and infarct percent
decreased significantly from baseline to 6 months in the
control group only, and there was significant difference
between the mBMC and control groups. Regionally,
infarct percent decreased significantly in the infarct zone
of the control group, and in the transmural infarct zone
of both groups. Infarct mass of the infarct zone decreased
significantly more in the control group than in the
mBMC group. In the group of patients with low baseline
EF, infarct percent in the infarct zone decreased more in
the controls than in the mBMC patients.
LV function
Average segmental strain at baseline is illustrated in
Figure 2b. Forty-six segments were excluded for strain
analysis at baseline, and 35 segments were excluded at
6 months. LV strain was analyzed in 26 patients.
Regionally, infarct zone strain and strain of remote
Table 1 Patient characteristics at admission
mBMC (n = 15) Controls (n = 13) p-value
Age - years 58.5 ± 8.9 58.7 ± 9.7 0.965
Female sex - no 3 3 0.843
Body mass index 25.7 ± 2.6 27.1 ± 3.2 0.240
Current smokers - no 5 3 0.836
Hypertension - no 2 3 0.502
Diabetes mellitus - no 1 1 0.916
Previous angina - no 2 4 0.262
Blood pressure - mm Hg
systolic 133 ± 21 125 ± 18 0.320
diastolic 79 ± 12 78 ± 13 0.807
Heart rate - beats/min 71 ± 12 80 ± 14 0.090
Time from symptom onset to PCI - min 239 ± 100 228 ± 112 0.780
Maximum creatine kinase MB - μg/l 382 ± 130 334 ± 143 0.376
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segments were analyzed in 27 patients. Thirteen patients
had 1 or more segments with more than 75% infarct,
and all were included for transmural infarct zone strain
analyses. The ICC of agreement for inter-observer judg-
ments was 0.97 (0.87-0.99) for global strain, 0.96 (0.83-
0.99) for infarct zone strain and 0.95 (0.65-0.99) for
transmural infarct zone strain. Corresponding ICC of
agreement for intra-observer observations was 0.99
(0.95-1.00), 0.98 (0.81-0.99) and 0.96 (0.82-0.99)
respectively. For individual segments agreement was
lower with an ICC of 0.81 (0.75-0.86) for intra-observer
and 0.87 (0.83-0.91) for inter-observer judgments.
LV function as measured by global strain improved sig-
nificantly from baseline to 6 months in the control group
(from -11.9 ± 3.4 to -13.1 ± 2.4%, p = 0.014), but remained
unchanged in the mBMC group. In the control group,
regional myocardial function improved significantly in the
infarct zone (from -9.3 ± 4.1 to -11.8 ± 3.0%, p = 0.001),
Table 2 Global and regional results; all patients (n = 28)
Baseline 6 months
mBMC controls p-value 1 mBMC controls p-value 2
Left ventricle
N = 28
EDV - ml 175.1 ± 48.7 176.8 ± 52.8 0.932 174.9 ± 60.0 174.3 ± 62.3 0.828
ESV - ml 91.2 ± 35.2 84.9 ± 41.0 0.668 87.6 ± 44.9 78.0 ± 42.3 0.674
EF - % 49.3 ± 9.5 54.1 ± 11.3 0.233 52.4 ± 11.9 57.9 ± 10.1 0.610
LV mass - g 168.6 ± 28.3 171.5 ± 42.1 0.831 162.4 ± 30.8 160.4 ± 41.1* 0.379
infarct mass - g 38.6 ± 23.3 45.7 ± 29.5 0.484 37.6 ± 20.5 35.7 ± 20.4* 0.034
infarct percent - % 22.1 ± 12.4 26.4 ± 14.8 0.410 22.2 ± 10.8 22.0 ± 11.0* 0.026
global strain - % -11.1 ± 2.4 -11.9 ± 3.4 0.512 -11.1 ± 2.6 -13.1 ± 2.4* 0.027
twist - ° 11.3 ± 3.6 12.8 ± 5.4 0.365 12.6 ± 4.3 11.8 ± 3.7 0.411
Infarct zone
N = 27
mass - g 103.0 ± 39.6 103.9 ± 37.6 0.955 100.3 ± 39.9 96.2 ± 34.5* 0.217
infarct mass - g 38.6 ± 23.3 45.7 ± 29.5 0.484 37.6 ± 20.5 35.7 ± 20.4* 0.034
infarct percent - % 34.4 ± 13.6 41.5 ± 17.7 0.242 34.3 ± 12.6 35.0 ± 11.6* 0.084
strain - % -9.7 ± 3.4 -9.3 ± 4.1 0.770 -10.2 ± 3.3 -11.8 ± 3.0* 0.009
Transmural infarct zone
N = 13
mass - g 32.3 ± 22.6 35.0 ± 26.2 0.855 33.7 ± 21.4 33.6 ± 24.0 0.519
infarct mass - g 29.0 ± 23.0 32.5 ± 25.2 0.804 26.6 ± 17.7 26.1 ± 19.5 0.468
infarct percent - % 86.8 ± 7.4 90.3 ± 6.1 0.377 77.6 ± 4.3* 76.6 ± 11.4* 0.401
strain - % -2.0 ± 1.5 -6.6 ± 5.6 0.107 -2.4 ± 1.4 -8.6 ± 4.9 0.108
Remote segments
N = 27
mass - g 64.4 ± 22.1 66.5 ± 24.3 0.816 61.1 ± 22.8 63.2 ± 24.0 0.965
strain - % -14.4 ± 2.4 -14.9 ± 2.3 0.560 -14.3 ± 3.3 -15.6 ± 2.3 0.195
p-value 1 refers to between group differences at baseline (two sample t-test). p-value 2 refers to between group differences in changes from baseline (analysis of
covariance). *p < 0.05 for intra-group changes from baseline, evaluated by paired sample t-test.
Table 3 Selected results; patients with baseline EF < median (51.9%)
Baseline 6 months
mBMC controls p-value 1 mBMC controls p-value 2
Left ventricle
N = 14
EDV - ml 183.2 ± 46.1 202.9 ± 49.3 0.641 194.6 ± 64.4 191.6 ± 55.6 0.162
ESV - ml 105.1 ± 33.1 114.8 ± 38.1 0.640 107.7 ± 43.4 95.2 ± 43.6* 0.028
EF - % 43.3 ± 6.4 43.7 ± 7.2 0.947 45.8 ± 7.1 51.9 ± 8.8* 0.386
infarct percent - % 28.8 ± 10.7 33.5 ± 12.1 0.505 27.2 ± 8.8 28.7 ± 12.1* 0.071
global strain - % -10.0 ± 2.4 -11.3 ± 2.9 0.536 -11.4 ± 2.8 -13.0 ± 2.8 0.189
Infarct zone
N = 14
infarct percent - % 41.0 ± 12.4 46.6 ± 11.9 0.463 37.9 ± 10.1* 38.8 ± 11.4* 0.053
strain - % -8.7 ± 2.9 -8.9 ± 2.7 0.738 -9.9 ± 3.1 -11.7 ± 2.4* 0.205
Transmural infarct zone
N = 9
infarct percent - % 86.8 ± 7.4 90.5 ± 7.7 0.462 77.6 ± 4.3* 79.2 ± 12.7 0.327
strain - % -2.0 ± 1.5 -4.6 ± 4.9 0.221 -2.4 ± 1.4 -8.6 ± 5.9 0.027
p-value 1 refers to between group differences at baseline (Mann-Whitney). p-value 2 refers to between group differences in changes from baseline (Mann-
Whitney). *p < 0.05 for intra-group differences from baseline, evaluated by Wilcoxon signed rank test.
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but not in the transmural infarct zone or the remote seg-
ments. Regional myocardial function remained unchanged
in the mBMC patients. In the group of patients with low
baseline EF, strain improvement was significantly more
pronounced for the controls in the transmural infarct
zone only. LV twist was analyzed in all 28 patients. Twist
was low at baseline for both groups, and did not change
significantly over time in either of the groups. The ICC of
agreement for inter-observer judgments was 0.92 (0.74-
0.98) and for intra-observer observations 0.96 (0.85-0.99).
The changes of LV strain in the control group corre-
lated significantly with LV infarction mass at baseline
and change of LV infarction mass (Table 4).
Discussion
The ASTAMI study, which included 100 patients, was
originally designed with a power of 80% to reveal a
potential difference of 5% points of LV EF development
between the mBMC and the control groups as measured
by single-photon-emission computed tomography. No
difference was found for global functional development
or for clinical parameters [2,21]. For LV EF inter-
observer variability was assessed with ICC of 0.85 (0.67-
0.93) for FLASH cines and ICC of 0.98 (0.96-0.99) for
trueFisp cines [2] (Supplementary Appendix). In this
substudy, only 28 patients were included, resulting in
reduced power. Unlike previous reports, myocardial wall
function developed beneficially for the control group as
compared with the mBMC group. Strain improvement
was 2.5 ± 2.0% points in the infarct zone and 1.6 ± 1.8%
points globally. Infarct mass as shown by LGE developed
similarly to strain, with a more pronounced infarct mass
reduction for the controls than for the mBMC group.
Both groups had a parallel, but statistically non-
significant trend towards LV EF improvement. The
results from this study illuminate the potentials for
detailed regional myocardial examination to detect subtle
differences of myocardial function not always detected by
other examination techniques routinely used.
Care must be taken drawing conclusions from the
results regarding development of myocardial function
and LGE in this study. Recently, Beitnes et al. published
results from the long-term follow-up of the ASTAMI
trial including global and regional LAD strain analyses
performed with longitudinal two-dimensional speckle-
tracking echocardiography (2D STE) [10]. They reported
a significant improvement of regional and global peak
systolic strain from baseline to 6 months, which was
maintained at three years post-infarction. However,
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Figure 2 Bull’s eye plots over baseline LGE and strain in the 16 LV segments model. 2 a: Average infarct involvement (percent) in each
segment (n = 448). 2 b: Average strain (percent) in each segment (n = 402). Negative strain values indicate myocardial shortening, and a strain
value with amplitude higher than -14% is considered normal.
Table 4 Correlation between strain development and
infarct mass in controls
Beta (standardized) R p-value
LV infarct mass at baseline -0.663 0.663 0.019
Change of infarct mass 0.665 0.665 0.018
Dependent variable: change of LV strain
Linear regression analysis for correlation between change of LV strain
(dependent) and baseline LV infarct mass and change of LV infarct mass in
controls (n = 12).
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there were no significant differences between the groups
regarding change in myocardial systolic or diastolic
function. The present substudy introduces some metho-
dological refinement to this study. Circumferential strain
was calculated from short axis CMR tagging versus
longitudinal strain calculation from long axis 2D STE.
For the regional CMR tagging analysis the infarct zone
was directly defined by findings from baseline LGE,
achieved during the same image session. Inter- and
intra-observer strain reproducibility was excellent for
global and regional strain analyses, even though repro-
ducibility decreased when strain was studied on the
individual segmental level. For the echo examination
there was no opportunity to directly delineate the myo-
cardial infarct area, and the region studied was the pre-
defined LAD territory. Additionally, strain calculations
were made at different time points. Baseline of the echo
study was 4.5 ± 1.1 days after the myocardial infarction,
before the bone marrow aspiration and intracoronary
mBMC injection of the mBMC group, whereas the base-
line CMR examination was performed at 18.8 ±
3.8 days. This fact is also relevant for the comparison of
the global LV volumetric analyses. Even though the
groups did not develop significantly differently, the
CMR examinations in the main ASTAMI study revealed
a larger increase of LV EF (1.2% vs 4.3%, p = 0.054),
and a larger decrease of infarct size (-2.3 vs -5.9 ml, p =
0.11) in the control group than the mBMC group [2].
There were no between-group differences in baseline
infarct mass in the larger, main ASTAMI study.
Although not significant, the baseline infarct mass in
the substudy was slightly, but not significantly higher in
the control group than in the mBMC group. Strain
values in the ischemic heart are closely related to LGE
[22-24], and strain improves over time after acute myo-
cardial infarction [25]. In the present study, there was a
significant correlation between improvement of strain
and reduction of infarct size in the control group
(Table 4). Part of the differences between the study groups
may have been caused by the small study group bias.
In the main ASTAMI study, 72% of the patients who
received intracoronary cell injections reported mild
chest pain during the procedure and 77% had transient
ischemic ST deviation during balloon inflation. No
patient had reinfarction related to the procedure [2].
Beitnes et al. recently reported no adverse effects
observed after three years in the same population [21].
Thus, there is no indication that the intracoronary bal-
loon inflation procedure has influenced the clinical
results of the mBMC group. The present study was not
designed to reveal any subtle immediate beneficial or
unfavorable changes in the myocardium after intracor-
onary injection of mBMC. One might speculate, how-
ever, that recurrent balloon inflations might negatively
influence myocardial function in the treatment perfusion
area, as indicated in our results.
Regional wall function has been investigated by differ-
ent means in other stem cell trials. In the Repair-AMI
trial regional function improved more in infarcted areas
in the stem cell group judged by the centerline chord
method at 4 months [6]. In a recent CMR substudy by
Dill et al., infarct area wall thickening was assessed by
cine CMR examination, and the results indicated more
pronounced increase of wall thickening in the stem cell
group after 12 months in the group of patients with
initial EF lower than median EF (48.9%) [9]. In the
BOOST trial, wall thickening and wall motion in
infarcted areas were studied by short axis cine CMR.
There was no significant treatment effect from stem cell
injection on global LVEF or on the regional function
parameters studied at 18 months or 5 years follow up
[7,26]. In the trial from Leuven wall thickening was
assessed by short axis cine CMR in transmurally and
non-transmurally infarcted segments. The change in sys-
tolic function did not differ at 4 months between the
stem cell group and the placebo group [5]. However,
there was a beneficial stem cell treatment effect on
strain as measured by tissue Doppler imaging for seg-
ments with initial LGE involvement of more than 75%
[8]. The results from our substudy do not support any
potential beneficial effect from intracoronary injection of
mBMC after reperfused myocardial infarction. This also
applies to the patients with larger transmural myocardial
infarcts and those with low EF.
End systolic LV twist is the difference in the systolic
clockwise rotational movement of the basal region from
the counter-clockwise rotational movement of the apical
region as seen from the apex. The rotation is part of the
complex wringing movement of the left ventricle during
systole [27,28]. Baseline end systolic LV twist values in
our study were 11.3 ± 3.6°and 12.8 ± 5.4°in the mBMC
group and controls, respectively. Despite lack of healthy
controls for comparison, we regard these values to be
clearly lower than the normal values as measured by
speckle-tracking echocardiography [29,30]. Reproducibil-
ity was excellent, with ICC of 0.92 and 0.96 for inter-
and intra-observer variability, respectively. Several
authors have found reduced twist in acute or chronic
myocardial ischemia compared with twist in healthy
individuals, and twist reduction is correlated to the
extent of LV EF reduction [29,31,32]. Twist and the
more simplified apical torsion have been suggested as
reliable and sensitive tools to detect LV dysfunction. In
a patient group of acute LAD myocardial infarction,
Han et al. found a positive correlation between LV EF
and twist, and in addition twist significantly improved
one month after revascularization, parallel to a mean EF
increase from 38.8% to 49.7% [33]. In the present study
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mean baseline EF was higher. Further studies, also dif-
ferentiating smaller from larger infarctions, are needed
to evaluate potentials and clinical significance for twist
development after acute myocardial infarction.
According to the standardized scheme for myocardial
territory assignment the LAD artery supplies the ante-
rior wall and the anterior part of the septum, as well as
the apical septum and the apical cap [15]. Ortiz-Pérez et
al. have suggested a modification to this scheme, adding
the mid anterolateral segment and the apical lateral and
inferior segments to the LAD territory [34]. Individual
variation will add complexity to these schemes in any
patient studies. In the present study, only patients with
their first ST-elevation anterior wall infarction were
included. Small, medium-sized and large infarcts were
quite evenly represented. The relative lack of basal slice
LGE in the small infarcts probably was a consequence
of the site for LAD occlusion. In the mid-ventricular
slices LGE of the anterior lateral wall and the inferior
part of the septum was of similar magnitude, and quite
significant. Visually, the LGE areas of these segments
were fringes of the LGE in the neighboring LAD terri-
tory segments. In the apical slices all segments were lar-
gely affected, supporting the modification suggested by
Ortiz-Pérez et al. [34]. As illustrated in Figure 2 average
reduction of segmental strain followed a pattern similar
to the average LGE involvement, although strain values
were relatively lower in the septum.
Limitations
The time point for the baseline CMR at least two weeks
after the acute event was chosen to reduce overestima-
tion of infarct size owing to tissue edema, and
T2-weighted sequences for evaluation of edema were
therefore not part of our protocol. Obviously, more
information on LV volumes and function could have
been available with an additional CMR examination
before or immediately after intracoronary cell injection.
Thus, we may have missed early and short term changes
after the injection, and thereby possible differences
between the groups, either related to stem cell effect, or
even to the intracoronary balloon inflation procedure
itself. This fact also is relevant for the direct comparison
between echo and CMR results. However, the time
point for baseline CMR examination was suitable for the
investigation of myocardial remodeling after the acute
phase. Serial CMR studies underscore the advantages of
examining LGE after the first 7 days of resorption
of necrotic myocardium and hemorrhage, reduction of
myocardial edema and possibly rescue of myocardium at
risk. A better correlation was found between later func-
tional parameters and LGE after one week compared
with LGE immediately after the infarction and reperfu-
sion [35-37].
Short duration of follow-up and a relatively small
number of patients, even reduced by exclusions from
tagging noise; make the present study insufficient in the
assessment of post mBMC treatment effects. LV EF was
examined with the area-length method, possibly adding
variability compared with multiple short-axis cines. Dif-
ferences in development may have been masked. The
selection of patients did not completely concur with the
main ASTAMI study, with a non-significant, numerically
slightly higher initial infarct mass in the control group
than the mBMC group.
Conclusions
The results from the present study do not support the
hypothesis that intracoronary mBMC injection after
reperfused anterior wall infarction reduces infarct size
or improves myocardial function. Findings from regional
LGE and strain analyses quite similarly demonstrate
subtle differences between the mBMC and control
groups with a slightly more favorable development in
the controls. The potential role for LV twist as assessed
by CMR tagging has to be evaluated in further studies.
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